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Abstract 
Lung cancer is the deadliest solid tumor, leading to the deaths of more individuals than the 
combination of the three next most lethal cancers which are colon, prostate and breast cancer. 
According to the IARC, in 2012 lung cancer accounted for 13% (1.83 million) of cancer cases and 
caused 19% (1.56 million) of cancer deaths worldwide. Despite advances in surgery and drug 
discovery, lung cancer remains difficult to treat. This is a result of unavoidable exposure to 
carcinogens, poor diagnosis and the lack of targeted drug delivery platforms. The aim of this study 
was to develop a non-invasive, patient convenient platform for the targeted delivery of 
chemotherapeutic drugs to cancer in deeper lung tissue. The formulation consisted of inhalable 
maltodextrin (MD)-based microparticles (MPs) encapsulating chitosan (CS) nanoparticles (NPs) 
loaded with magnetic nanoparticles (MNPs) and a chemotherapeutic drug. Ionotropic gelation was 
used for CS NPs synthesis. MNPs were synthesized via hydrothermal method and they were 
superparamagnetic with magnetic saturation (Ms), coercivity (Hc) and remanence (Mr) of 48.4 
Am
2
/Kg, 9.9x10
-4
 T and 0.5 Am
2
/Kg emu/g; respectively. CS NPs provided a sustained release of 
drug, whereas MNPs encapsulated in CS NPs were able to increase the NP drug release in response 
to an external magnetic field by 1.7 fold. Cell uptake studies conducted using lung cancer cells 
(A549) indicated that the CS NPs are rapidly uptaken, and show preferential toxicity to tumor cells in 
comparison to cultured fibroblasts. NPs were modified with anti-epidermal growth factor receptor 
antibodies and this modification showed to hinder cellular uptake of NPs. Afterwards, the prepared 
CS NPs and CS-MNPs were co-spray freeze dried (SFD) with MD. The prepared SFD powders had 
fine particle fraction (FPF ≤ 5.2 µm) of 40-42 % w/w and mass median aerodynamic diameter 
(MMAD) of 5-6 µm as determined by the next generation impactor (NGI). A mixture of CS NPs and 
CS-MNPs could be able to provide a continuous sustained release of drug, with intermittent blouses 
of drug in response to external stimuli; a drug profile desirable in cancer therapy. In conclusion, the 
targeted delivery to the lung cancer using the developed formulation seems to be a 
promising approach.
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Chapter 1: Introduction and Literature Review 
1. Lung Cancer: 
1.1. Burden: 
The dread and terror that come with a cancer diagnosis have their roots in its killer 
nature. Though tragic in general some types of cancer seem to have a lighter impact on 
patients’ ears than others; lung cancer surely not included. Lung cancer is the deadliest solid 
tumor, leading to the deaths of more individuals than the combination of the three next most 
lethal cancers which are colon, prostate and breast cancer [1]. As stated by the International 
Agency for Research on Cancer (Figure 1) in 2012, lung cancer accounted for 13% (1.83 
million) of cancer cases and caused 19% (1.56 million) of cancer deaths worldwide [2]. The 
numbers seem to leap; the World Health Organization estimates that lung cancer will 
account for 19.35% of all cancer deaths by 2020 [3]. Elevated lung cancer cases and 
associated deaths could be attributed to a number of reasons. Poor diagnosis; because the 
lungs are large, tumors can grow undetected for a while. In addition to that symptoms are 
unspecific (coughing and fatigue), failing to illicit serious worry [4]. For such reasons, 
early-stage lung cancer is difficult to detect. Smoking and increased exposure to 
carcinogens are other main causes [5]. The lungs’ epithelial surface represents the largest 
surface area of the human body, being concurrently in direct contact with the environment 
[6] makes inhalation the most important exposure route for airborne carcinogens such as 
such as arsenic, asbestos, polycyclic aromatic hydrocarbons, and radon [2, 7].  
1.2. Pathophysiology: 
Lung cancer’s pathophysiology can be described as a “multi-hit” condition; where 
several carcinogens (from different sources) induce genetic mutation affecting essential 
biological mechanisms such as growth control, vascular supply, proliferation and death of 
normal cells. Along with genetic susceptibility, the cumulative effect of several “hits” 
results in irreversible effects; dysregulation of these mechanisms and cancer development 
[8]. 
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1.3. Lung cancer classification: 
There are two types of lung cancer: small cell lung cancer (SCLC) and non-small cell 
lung cancer (NSCLC). NSCLC represents 85% of the lung cancer cases [9]. NSCLC is 
further divided into 3 main subtypes; squamous cell lung carcinoma (SCC), adenocarcinoma 
(AC) and large cell carcinoma with SCC and AC being the most common. SCC comprises 
approximately 30% of lung cancers and generally arises centrally within the lungs inside a 
large bronchus. AC, represents almost 30% of invasive lesions, tends to occur in more 
peripheral locations arising from the smaller airways but they can be found centrally in a 
main bronchus. In other words, regardless to its histology most lung tumors seem to allocate 
in the airways [9-10]. A possible reason is that inhaled carcinogens primarily come in 
contact with the epithelial lining of the lung airways resulting in molecular changes and 
genetic mutations within these cells leading to inflammatory responses in this area followed 
by progressive proliferative epithelial reactivity. The resulting epithelial lesions grow over 
time from hyperplasia to advanced preneoplastic lesions, and finally to AC and SCC [11]. 
Since the late 1990s, NSCLC has been commonly staged according to the fifth edition of the 
TNM classification system, which measures the size of the primary tumor (T), the extent of 
lymph node involvement (N), and the presence of distant metastases (M). Figure 2 
summarizes the classification system [12]. 
2. Chemotherapy in NSCLC: 
Accurate staging of lung cancer according to TNM staging is essential for deciding 
appropriate therapy [13]. Till this moment, surgical resection is considered as the most 
successful and consistent option for lung cancer diagnosed patients.  However, this option is 
limited by the feasibility of cancer being resectable, and the tolerability of patient to the 
proposed surgical intervention, making surgery only possible for patients with stages I-
II[13] or I-IIIA[14]. However, almost 70% of lung cancer patients at the time of diagnosis 
show up with locally advanced disease rendering surgery inappropriate [13]. Even in cases 
where surgery is a valid option, about 50% of the patients experience  recurrence within 5 
years after tumor resection [14]. For such reason adjuvant chemotherapy is generally 
accepted for patients with resectable stage IIA-IIIA NSCLC [13-14] and is thought to 
increase survival rates and reduce recurrence. Neoadjuvant, or induction, chemotherapy 
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administered preoperatively has also been proposed since it may render inoperable tumors 
resectable and improve the success of surgery by reducing tumor size and the occurrence of 
residual micrometastases [14].  
3. Drawbacks of intravenously (I.V.) administered chemotherapy: 
Several chemotherapeutic drugs are suggested for the use in NSCLC including cisplatin, 
etoposide, mitomycin C, vindesine, vinorelbine, vinblastine, and ifosfamide. There seems to 
be a consensus on the use of cisplatin based therapy in NSCLC; a series of trials conducted 
between 1991-2007 all have included cisplatin in their regimens [15-21]. Cisplatin is a 
platinum-containing anticancer drug which was discovered by Michele Peyrone in 1845 has 
water solubility of 2.5 mg/ml and is renally excreted. It acts by crosslinking DNA via 
binding Pt
2+ 
to the guanine bases of DNA interfering with cell division of cancer cells and 
elicit repair mechanism which will induce apoptosis of the cancer cells [22]. 
Although cisplatin-based chemotherapy reduces the risk of death from NSCLC by 
approximately 5%, considerable toxicity is unfortunately associated with platinum-based 
chemotherapy, which resulted in discontinuation of therapy in many patients [14]. Side 
effects include interstitial pneumonia, bone marrow suppression, hair loss, nephrotoxicity, 
myocarditis, and neurotoxicity all of which are a result of systemic dissemination of the 
drug following I.V. administration [9]. It is important to emphasize that the access of 
systemic intravenous drugs to tumors is surprisingly limited. Primeau et al.[23] utilized an 
immunofluorescent technique to assess the access of doxorubicin to tumors via the 
circulatory system. The authors found that an exponential reduction in the concentration of 
drug was visualized at a distance from tumor blood vessels; decreased to half the 
perivascular concentration within only 40–50 μm. Such findings raise several questions. Is it 
a delivery problem? Would chemotherapeutic drugs have a larger impact on survival rates if 
they actually reach the tumor?  Would targeted delivery provide a higher therapeutic value 
with less systemic side effect?  
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4. NSCLC targeting; Endobronchial intratumoral chemotherapy (EITC): 
Currently in the eyes of physicians, a benefit is granted by adjuvant chemotherapy that 
is equivalent to the cancer recurring risk; a higher risk cancer is more likely to have. The 
risk is reduced by chemotherapy to an extent that counterbalances the acute and chronic 
adverse effects of adjuvant chemotherapy. In other words, adjuvant chemotherapy is quiet 
beneficial but, its use is only hampered by its inability to reach its target and consequently 
cause intolerable systemic side effects. Such problems possibly ailed with the use of 
targeted delivery system, concentrating the drug and its actions to the tumor only, 
circumventing its distribution throughout the body and avoiding excruciating side effects.  
Literature includes several attempts in localized chemotherapeutic drug application. 
Celikoglu et al.  elegantly  summarized advances in EITC where chemotherapeutic drugs 
are intratumoraly injected into tumor tissue directly through a flexible bronchoscope by 
means of an ordinary needle-ended-catheter [9]. Precise cancer drugs delivery into the 
tumor is afforded by EITC,  where complete lesion perfusion, increased intratumour drug 
concentrations, and most importantly decreased toxic side effects which normally occur 
with conventional systemic chemotherapy can be obtained [9].  
Unfortunately EITC utilizes a bronchoscope rendering it an invasive technique. Though 
minimally invasive, the technique still mandates the availability of the patient in a 
bronchoscopy facility which makes the treatment modality far from convenient for patients 
and having a negative impact on patient compliance. Apart from that, bronchoscopy in 
particular is known to spike patient anxiety with sedating medicaments such as midazolam 
usually prescribed pre- procedure, making the treatment modality far less appealing for such 
patients [24]. In simpler words for efficient treatment a cancer patient would have to visit 
the EITC facility several times a month (possibly a week) and go through an invasive, 
discomforting procedure on a regular basis for a long time. Patients also complain from, 
sensation of nausea, moderate chest pain, and a moderate fever after the procedure [9], 
though not quiet problematic, all of which are trivial forms of pain and discomfort that 
could be spared by a cancer patient. 
It is true that EITC initially delivers large amounts of chemotherapeutic drug into the 
tumor, however the drug seems to diffuse of from the injection site [9]. A prolonged high 
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intratumoral drug concentration from few hours to several days is desirable for more 
effective treatment. In attempt to do so several researchers have tried intratumoral injection 
of gel containing drugs [25-26] and microspheres [27]. Such attempts though ail the drug 
diffusion problem, show no improvement of the drawbacks of the bronchoscopy based 
technique. 
5. NSCLC targeting; Oral chemotherapeutic drugs? 
An efficient targeted delivery platform is therefore required to deliver chemotherapeutic 
drugs to lung tumors in the most comfortable and convenient way. Compared to systemic 
administration and bronchoscopy based procedures, the oral route is more patient 
friendly.  A patient interview conducted on 103 patients showed that the oral route was 
preferred by the majority of patients (90%), mainly due to greater convenience (57%), 
intravenous access problems such as fear of needles (55%) or medicament administration at 
better environment (i.e., the home setting) [28]. However for chemotherapeutic drugs the 
oral route does not present itself as the most efficient. Apart from concerns about drug 
absorption, bioavailability and general random pharmacokinetics, orally administered 
chemotherapeutic drugs ultimately reach the blood and are distributed systemically with 
minimal amounts reaching the lung in general and the tumor in particular. Thus, only 
solving the problem of impracticality but not the intolerable side effects and low target 
accessibility [29]. 
6. NSCLC targeting; Inhaled nanoparticle (NP)/microparticle (MP) based 
chemotherapy: 
Inhalation was believed to be the optimal route of administration in the case of NSCLC 
chemotherapy and that use of the creatively engineered inhalable particulate carriers may in 
fact hold the solution to the current dilemma. Inhalation offers a non-invasive route for 
chemotherapeutic drug delivery lacking the undesirable attributes of I.V. and bronchoscopy 
based approaches. The use of particulate carriers affords specific tumor targeting and a 
tailored drug release profile. Moreover, it provides a non-invasive method for targeted 
delivery of chemotherapeutic drugs to the lungs, with minimal systemic side effects and 
patient inconveniency. Since most of NSCLC are AC and SCC and most of which seem to 
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allocate in the airways [9-10], the development of NP/MP carrier system capable of 
delivering chemotherapeutic drugs to airway tumors is a valid approach. To further 
elaborate on how airway targeting could be achieved, first light is needed to be shed on the 
in-vivo fate on inhaled NP/MPs. 
6.1. In-vivo fate of inhaled particulate carriers: 
The fate of inhaled NPs and MPs depends on where they initially deposit in the lungs and 
how they are cleared, the latter is being greatly dependant on the former and both are being 
a function of the particle’s physico-chemical properties and lung anatomy [30-32]. The 
epithelium in the trachea and bronchial area is protected by a ciliated mucus layer. 
Therefore, rapid clearance of particles depositing in the upper airways by the cilia results 
within the mucus layer, moving them to the throat, where they are swallowed and 
metabolized eventually [30-31]. Deposition of inhaled particulate system in the lung is 
achieved by any of the following mechanisms; inertial impaction, gravitational 
sedimentation and Brownian diffusion [31].  Deposition mechanism followed by the 
particulate system depends on its aerodynamic diameter (AD); a parameter greatly 
dependant on particle density, material of synthesis, geometrical diameter, and shape [32-
33]. By inertial impaction particles with ADs larger than 5 µm mainly deposit in the large 
airways and oropharynx, in which they will most likely be cleared through mucocillary 
clearance instead of reaching the lung [32]. Those with ADs ranging from 1-5 µm deposit 
by gravitational sedimentation and diffusion deeper into the lungs [31-32, 34-35]. As for 
NPs most of them will be exhaled as a result of their small size, however they can still be 
delivered to the lung by being incorporated into larger particles with appropriate AD or 
nebulization [32, 36]. Though hard to sediment in the lungs, it has been demonstrated by 
several studies that small NPs are able to overcome steric inhibition possessed by the dense 
mucin fiber mesh [37-38], moving into the mucus layer where they interact with the non-
phagocytic cells of the epithelium and their endocytosis will be regulated by clarithin coated 
pits, caveolae and scavenger receptors, allowing them to gain access into the pulmonary 
interstitium [31].   Particle deposition is also highly influenced by surface electrostatic 
charge; higher deposition efficiencies is achieved by the charged NPs rather than neutral 
ones [31]. In other words charged NPs have a greater chance in allocating into airway cells 
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and in this case in NSCLC cells, they do however lack the desirable AD for deposition in 
the airways.  
6.2. The Proposed Formulation: Nanoparticle embedded in microparticles 
(NEMs) for airway tumor delivery: 
The formulation of chitosan NPs (CS NPs) encapsulating a chemotherapeutic drug and 
magnetic NPs (MNPs) all enclosed in Maltodextrin (MD)-based MPs (CS-MNPs-MPs) and 
CS NPs encapsulating a chemotherapeutic drug only enclosed in MD MPs (CS NPs-MPs) 
(Figure 3) was proposed. 
6.2.1. Why CS NPs? 
CS is obtained from deacetylation of chitin which is the main component of crustaceans’ 
shells. It is a linear polysaccharide composed of randomly distributed β-(1-4)-linked N-
acetyl-D-glucosamine and D-glucosamine. As a result of its water solubility, 
biocompatibility and biodegradability it has been used in various biomedical applications. 
Molecular weight and degree of deacetylation of CS affect its properties whether chemical 
or biological and classify commercially available CS into high, medium and low molecular 
weight CS with molecular weight and degree of deacetylation are decreasing respectively. 
Since molecular weight and degree of deacetylation of CS affects NPs degradation, 
therefore medium molecular weight CS was preferred for moderate degradation and drug 
release for the sustained release purpose aimed by synthesized CS NPs for continuous 
supply of chemotherapeutic drug to lung cancer cells. Sustained drug delivery together with 
the mucoadhesive property of CS that allows prolonged contact time with cell surface for 
continuous drug release, render CS NPs as the optimum type of NP for chemotherapeutic 
drug delivery in NSCLC [39]. 
6.2.2. Why MNPs? 
MNPs have been recently used in various biomedical applications such as magnetic 
hyperthermia, drug targeting, MRI enhanced imaging and cell separation [40]. For these 
biomedical applications it is preferred for MNPs to possess superparamagnetic characteristic 
to avoid aggregation in organs or vascular system resulting in unwanted side effects after 
the removal of externally applied magnetic field. Toxicity of MNPs depends on several 
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factors among which are the shapes, size, materials used for synthesis and degradation 
byproducts of MNPs. Therefore, green synthesis method that is devoid from any organic 
solvents is important to reduce cytotoxicity of MNPs. The use of small sized MNPs (< 20 
nm) for superparamagnetic behavior will ensure rapid renal clearance of MNPs from the 
body after their use as a result of their small size, thus accumulation of MNPs in the body 
will be avoided. Knowing that MNPs are made up of iron which is the main component of 
hemoglobin, byproducts from MNPs degradation can be stored in the liver to be used later 
for red blood cells production [41]. 
6.3. Route and method of administration: 
CS-MNPs-MPs and CS NPs-MPs are to be co-administered using a dry powder inhaler.  
6.4. Deposition in the lung: 
MPs with AD 1-5 µm deposit by gravitational sedimentation and diffusion deeper into 
the lungs [31-32, 34-35]. MD MPs developed with mean AD ranging from 1-5 µm will 
allow deposition in the airways. MD is a soluble sugar and upon contact with lung lining 
fluids the MPs will dissolve liberating the cationic CS NPs. Similar attempts utilizing 
NEMS proved success of the concept with the use of lactose [42] and mannitol [43] for MP 
synthesis. 
6.5. Specific targeting and entry into tumor cell: 
CS is a biodegradable non-toxic cationic polymer [44] yielding positively charged 
hydrogel NPs [45]. Since charged NPs are more readily up taken by airway cells than 
neutral larger particles then CS NPs are a valid approach. To further augment cellular entry 
and increase specificity to tumor cells CS NPs are to be conjugated with a targeting moiety.  
From the tyrosine kinase ErbB family, epidermal growth factor receptor (EGFR) is 
abnormally activated in many epithelial tumors (Figure 4) [46]. EGFR was found to be 
over-expressed in samples and cell lines of NSCLC, and associated with increased tumor 
proliferation, higher incidence of metastases to lymph nodes, poor differentiation, and a 
worse prognosis [47]. Surface conjugation of an EGFR specific ligand would further 
facilitate tumor localization into NSCLC cells by receptor mediated endocytosis. 
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6.6. Drug release and theranostic potential: 
One of advantages of EITC is its ability to deliver a large bolus of drug into the tumor. 
Instantly after cytotoxic drug solution injection, the tumor shrinks to a smaller volume. It is 
assumed that these rapid effects result from direct contact of malignant cells to extremely 
high concentration of anticancer drug. It is believed that  a transient super-dose spike of a 
few minutes in the tumor have more tumoricidal effect than tolerable doses of I.V. drugs 
[9]. However as mentioned earlier with EITC the drug diffuses from the injection site [9], 
making the technique incapable of the desirable continuous supply of chemotherapeutic 
drug. The importance of the latter made quite obvious by the continued efforts to develop 
chemotherapeutic drug sustained release dosage forms [48-49]. 
Co-administration of our proposed formulations CS-MNPs-MPs and CS NPs-MPs would 
provide an initial bolus dose, followed by a sustained release of the chemotherapeutic. CS-
MNPs-MPs provide the initial bolus in the response to alternating magnetic field while CS 
NPs-MPs provide the sustained supply of drug (Figure 5). Physical stimuli (such as; 
ultrasound, temperature, light, magnetic and electrical fields) induce polymer response by 
directly modulating the energy level of the polymer/solvent system to critical energy level 
[50]. When CS-MNPs released from CS-MNPs-MPs are subjected to an alternating 
magnetic field, heat is produced either by hysteresis loss or by Néel (spin rotation) and 
Brownian (particle rotation) relaxations based on the material of enclosed MNPs [51]. This 
property is measured in terms of specific loss power (SLP) which depends on nanoparticles 
size (i.e. core radius, r), saturation magnetization (Ms), magnetic anisotropy constant (K) 
and solution volume [51-52]. This released heat can result in the swelling, collapse or 
degradation of temperature-responsive hydrogel NPs [50] and rapid release of the 
encapsulated drug; initial bolus. In addition to rapid drug release, the elevated temperature 
may actually participate in tumor cell ablation; magnetic hyperthermia [52]. Enhanced 
relaxivity coefficient (r2) possessed by MNPs may also add the advantage for CS-MNPs-
MPs to serve as contrast agents for imaging modalities such as magnetic resonance imaging 
(MRI) [52]. An image-guided drug release triggering with the provision of information 
regarding the anatomical location of the carrier system would be allowed by MNPs 
incorporation. By this means diagnostic feature or in this case theranostic feature can be 
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imparted. Co-administered MNPs-free CS NPs-MPs provide a sustained release of 
chemotherapeutic drug complementing the targeted bolus dose supplied by CS-MNPs-MPs. 
7. State of the art: 
Lung cancer targeting has been addressed previously in different studies where various 
biodegradable NP/MP drug delivery platforms were developed as summarized in Table 1. 
In this section the short comings of the published delivery devices that are addressed by our 
proposed formulation will be highlighted. 
Although the above formulations offer improved therapy, they lack the advantages 
provided by the use of MNPs; the initial bolus release of chemotherapeutic drug in addition 
to the possible extra tumoricidal benefit due to magnetic hyperthermia and 
diagnostic/prognostic benefits. Except for studies performed by  few authors ( Sadhukha, T., 
et al [64], Nejati-Koshki, K., et al [65], and McBride, A.A., et al [69]) in which the use of 
MNPs was included however, they did not assess MNPs cytotoxicity on normal cells. 
Some studies showed the potential of formulating inhalable formulations. They were 
administered using either aerosolizers or nebulizers, this is limited by the suspension and 
storage of NPs in liquid suspensions which will cause (1) Drug release and deactivation in 
aqueous media (2) Particle degradation or swelling [53-54, 70, 77]. Study performed by 
Kaminskas, L.M., et al [55], showed delivery platform to be administered via intratracheal 
instillation. Beside possessing same limitations as aerosolizers and nebulizers in suspending 
and storing NPs in liquid medium this route of administration is considered to be invasive.  
Other reports utilizing NP based platforms have also been reported, however they mostly 
utilize the IV route and therefore are thought to hold all the undesirable attributes mentioned 
earlier [60-62, 66-67, 73-75]. In some of them cytotoxicity of the formulation was not 
evaluated to determine tumor-platform specificity. Few studies have developed dry powder 
inhalable platforms such as our proposed formulation [56, 68-69, 76].  
Authors in some of their studies also did not assess drug release profile of NPs to 
determine therapeutic efficacy of the developed platform [53, 55, 63, 66, 68, 76].   Even if it 
is known that polymer used will exhibit a sustained drug release profile, only one part of the 
desired drug supply regimen will be fulfilled with insufficient bolus dose of chemotherapy.   
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In some studies NPs were prepared using toxic chemicals such as glutaraldehyde [54, 75] 
which is considered to be unattractive for in-vivo administration of the therapeutic platform. 
For lung tumor-targeted delivery, EGF ligand was used as a targeting moiety in one of the 
studies [54, 77]. However, this could be associated with the risk of cancer growth induction. 
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Thesis Scope and Objectives 
The main aim for this study was to develop a non-invasive, patient convenient platform 
for the targeted delivery of chemotherapeutic drugs to NSCLC. The delivery platform 
should be able to provide an initial high dose of chemotherapeutic drug that is controllable 
in response to external stimulation followed by a sustained supply of the drug in the tumor, 
all whilst providing a diagnostic edge; allowing physicians to actually see the tumor, which 
does not only assure success of delivery but may be of prognostic value. Therefore the 
formulation and optimization of CS NPs encapsulating a chemotherapeutic drug and MNPs 
all enclosed in MD MPs (CS-MNPs-MPs) and CS NPs encapsulating a chemotherapeutic 
drug only enclosed in MD MPs (CS NPs-MPs) was proposed. 
The proposed delivery platform; 
  Utilizes the inhalation route; non-invasive, convenient and could be administered 
at home, which in turn increases patient compliance. 
 Specifically targets airway NSCLC cells, minimizing systemic side effects, 
lowering the overall dose and ultimately reducing patient expense. 
 Exhibits a desirable drug release profile; initial bolus followed by a sustained 
supply of chemotherapeutic drug. 
 May have an increased effect on tumor cell destruction by action of the MNPs; 
magnetic hyperthermia. 
 Provides an idea about tumor size, location making it a diagnostic and therapeutic 
platform; theranostic. Could also be used to monitor tumor shrinkage and 
prognosis, giving an idea about patient response to the administered drug and 
possibility of regimen modification/ tailoring. 
 Is expected to show minimal toxicity since it is formulated utilizing a green 
synthetic method devoid of any organic solvents and with biocompatible, 
biodegradable polymers. 
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The intended delivery platform was obtained in this thesis by achieving the following 
milestones: 
1. Preparation and characterization of Chitosan Nanoparticles. 
2.  Preparation and characterization of Magnetic Nanoparticles. 
3. Preparation and characterization of Drug-loaded Chitosan Nanoparticles and 
Chitosan-Magnetic Nanoparticles. 
4. Tagging Nanoparticles with epidermal growth factor-antibody. 
5. Nanoparticles in-vitro uptake by lung cancer cells. 
6. Characterization of incorporated Nanoparticles in Microparticles. 
 
  
 14 
 
 
Chapter 2: Materials and Methods 
1. Materials: 
Medium molecular weight chitosan (CS) (190-310 kDa) was purchased from Bio Basic 
Inc. (Ontario, Canada). Sodium Tripolyphosphate (TPP) was bought from Mistral 
(Northern Ireland, UK). Glacial acetic acid was purchased from El-Gomhouria Co. (Cairo, 
Egypt).  
Iron (III) Chloride Hexahydrate (FeCl3.6H2O), Sodium Bicarbonate (NaHCO3), and L-
ascorbic acid/Vitamin C (Vit C) were supplied by Sigma-Aldrich (Munich, Germany). 
N-acetyl-L-cysteine (NAC), sodium phosphate dibasic dihydrate, Ellman’s reagent, FL, 
and sodium hydroxide (NaOH) were supplied from Sigma-Aldrich (Munich, Germany). 
Disodium Ethylenediaminetetraacetate (EDTA) was purchased from Fisher Scientific 
(Waltham, MA, USA). Spectra/Por Float-A-Lyzer G2 (MWCO 100 kDa) was supplied from 
Spectrum Laboratories Inc. (Schwerte, Germany). 
Anti-mouse IgG (whole molecule) - Fluorescein isothiocyanate (IgG-FITC), monoclonal 
anti-epidermal growth factor receptor antibody (EGFR-Antibody or Ab), and N-(3-
Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC) were purchased from 
Sigma-Aldrich (Munich, Germany). 
Phosphate buffered saline (PBS), RPMI 1640 with L-Glutamine, Pen-Strep, L-
Glutamine, and Trypsin EDTA were purchased from Lonza (Basel, Switzerland). Fetal 
Bovine Serum (FBS), Hoechst 33258, Pentahydrate (bis-Benzimide) and Wheat Germ 
Agglutinin, Alexa Fluor 488 Conjugate (WGA-AF) were supplied by Life Technologies 
(Carlsbad, CA, USA). 6 Well Cell Culture Plate, sterile, F-bottom with lid, 96 Well Half-
Area Black Microplate, clear F-bottom with lid, 96 Well Microplate, U-bottom without lid, 
96 Well Cell Culture Plate, sterile, F-bottom with lid and T25 and T75 tissue culture flasks 
were from Greiner Bio-One (Monroe, NC, USA). 3-(4, 5-dimethylthiazolyl-2)-2, 5-
diphenyltetrazolium bromide (MTT), Dimethyl sulfoxide (DMSO), Cis-Diammineplatinum 
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(II) Dichloride (Cisplatin), and methanol were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Trypan Blue Solution was from Fluka (St. Louis, MO, USA). A549 and L929 
cell lines were obtained from Vacsera Holding Company (Cairo, Egypt) and the American 
Type Culture Collection (Manassas, VA, USA); respectively. 
Maltodextrin (MD) and Polyvinylpyrrolidone (PVP) were bought from Sigma-Aldrich 
(St. Louis, MO, USA).   
2. Methodology: 
2.1. Nanoparticles (NPs) formulation and characterization: 
2.1.1. Chitosan Nanoparticles (CS NPs): 
The nanoparticles (NPs) were prepared by the ionotropic gelation of chitosan (CS) and 
tripolyphosphate (TPP).  CS and TPP of different concentrations (0.1, 0.3, & 0.5 % w/v for 
CS and 0.04, 0.08 & 0.1 % w/v for TPP) and pH (3, 4 & 5 for CS and 5 & 8 for TPP) were 
prepared. CS was dissolved in 1 % acetic acid, while TPP in de-ionized (DI) water. For each 
formulation, 2 ml of TPP solution were added directly to 5 ml of CS solution. The mixture 
was stirred for 30 min at 400 rpm at room temperature using magnetic stirrer (VWR 
Scientific, PA, USA). CS NPs formation was determined initially through the appearance of 
obtained solution.  Opalescent solution indicates the formation of CS NPs, otherwise either 
clear solution lacking CS NPs or aggregate is obtained [78].  
The NPs morphology and size of different formulations were first determined using 
Field Emission-Scanning electron microscope (FE-SEM), (SUPRA 55, ZEISS, Jena, 
Germany). A drop from the NPs was placed on a SEM silicon wafer and left to dry. Then 
the samples were examined using FE-SEM. NP’s hydrodynamic diameter and zeta potential 
were then evaluated using Dynamic Light Scattering (DLS) and Laser Doppler 
Electrophoresis (LDE); respectively (Zeta sizer nano series (Nano ZS), Malvern 
Instruments Ltd., Worcestershire, UK). For DLS 1 ml of freshly prepared formulation was 
used and 1 ml of purified NPs (centrifuged and re-suspended in DI water) was used for 
LDE. To validate reproducibility triplicate samples were analyzed and the S.D. value of the 
three was adopted. Atomic Force Microscope (AFM), (Nanoscope IIIa, Veeco, NY, USA) 
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was used for further assessment. Sample for AFM was diluted in 1:10 ratio using DI water. 
A drop from diluted sample was placed on a clean microscopic glass slide and left to dry in 
the air. Samples were observed by AFM in tapping mode. 
2.1.2. Magnetic Nanoparticles (MNPs): 
The MNPs were synthesized via chemical reduction of Fe(OH)3 using L-ascorbic acid 
(i.e. Vitamin C) to obtain water-dispersible, biocompatible  ultrasmall superparamagnetic 
iron oxide nanoparticles (USPIONs) of 2-5 nm. To obtain biocompatible USPIONs, 
different formulations were tried out with varying parameters such as autoclaving time (4 & 
6 hrs) and temperature (150 & 200°C), FeCl3.6H2O concentration (0.1 & 0.3 M) and 
FeCl3.6H2O: Vit C molar ratio (6:1, 1:6, 1:1 & 2:1) to reach NPs with optimal 
characteristics. Aqueous solutions of FeCl3.6H2O, NaHCO3 and Vit C were prepared in DI 
water. 
For each formulation, 20 ml of 0.45 M NaHCO3 were added drop wise to 10 ml of 
FeCl3.6H2O to change soluble FeCl3 into Fe(OH)3 precipitate. The mixture was stirred for 1 
hr at 400 rpm at room temperature. Subsequently, 5 ml of Vit C were added drop wise and 
the whole mixture was left to stir for further 20 min. Following this 30 ml of the mixture 
was transferred into a 50-ml steel-lined Teflon autoclave tube. The Teflon tube was then 
placed in the autoclave after adjusting its temperature and timing. After the synthesis, the 
MNPs were washed with DI water and ethanol three times each and were collected by 
centrifugation eventually at 11 000 rpm (Centrifuge 5804, Eppendorf, Hamburg, Germany). 
The obtained precipitate was easily re-dispersed in DI water by ultrasonication (Ultrasonic 
Sonicator, SONOREX, BANDELIN electronic, Bandelin, Germany). After re-dispersion, 
external magnet was applied to confirm MNPs synthesis.    
NPs hydrodynamic diameter was initially assessed by DLS. The NPs surface charge was 
determined by LDE. For both DLS and LDE, 1 ml of ultrasonicated 0.357 mg/ml stock 
solution of MNPs in DI water was used. Samples were analyzed in triplicates to validate the 
formulation’s reproducibility. The morphology and actual size of the optimum formulation 
was examined using Scanning Transmission Electron Microscope (STEM), (CM300 
FEG/UT, Philips, Eindhoven, Netherlands). A drop of MNP concentration used for DLS 
and LDE was placed on a carbon coated film 300 mesh copper grid, and left to dry at room 
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temperature. The transformation of FeCl3.6H2O and Vit C into iron oxide NPs capped with 
oxidized Vit C (dehydroascorbic acid, DHAA) has been analyzed by Fourier Transform-
Infrared Spectrometer (FT-IR), (PerkinElmer, MA, USA). MNPs were then examined by 
Vibrating Sample Magnetometer (VSM), (7410, Lake Shore Cryotronics Inc., IL, USA) 
(0.05 g) and X-ray Diffractometer (XRD), (XPERT-PRO, PANalytical, Almelo, 
Netherland) (0.1 g) to determine MNPs magnetic properties and crystalline structure 
respectively. 
2.1.3. Void MNPs-loaded CS NPs (CS-MNPs): 
Different amounts of MNPs as a percentage of the CS mass were encapsulated in CS 
NPs. Since MNPs were negatively charged, thus different amounts of MNPs (0.5, 1 and 2 
mg which were equivalent to 10, 20, and 40 % of CS mass; respectively) were added to 5 ml 
0.1 % CS solution (pH 5). Then 2 ml of 0.1 % TPP solution (pH 5) were added directly to 
the CS solution containing MNPs. The mixture was stirred for 30 min at 400 rpm at room 
temperature.  
Obtained NPs hydrodynamic size, zeta potential and morphology were examined using 
DLS, LDE and High Resolution Transmission Electron Microscope (HR-TEM), (2100, 
JEOL-JEM, Herts, UK) respectively as detailed earlier. For DLS and LDE samples were 
analyzed in triplicates and results were presented as mean ± S.D. 
2.2. Drug loading and its effect on NPs physicochemical properties: 
2.2.1. Encapsulation Efficiency % (EE %) of CS NPs: 
N-acetyl-L- cysteine (NAC) and fluorescein (FL) were chosen as model drugs (Figure 
6) due to ease of quantification using sulfhydryl detection reagents and ease of cellular 
uptake evaluation for NPs; respectively.  Similarly as CS NPs, drug-loaded NPs were 
formulated using ionotropic gelation.  
For drug-loaded NPs;   NAC/FL was initially added to 5 ml 0.1% CS solution (pH 5). To 
CS-drug solution, 2 ml 0.1% solution of TPP (pH5) were added all at once and stirred using 
magnetic stirrer for 30 min at 400 rpm at room temperature. NPs synthesis was confirmed 
by opalescent appearance. Different concentrations of NAC (7, 10 & 12 mg/ml) and 100 µl 
of FL (2 mg/ml in 0.01 M NaOH) were used to evaluate NPs EE %. For each sample 
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duplicates were analyzed and the S.D. of each duplicate was adopted to validate EE %’s 
reproducibility of the CS NPs.   
EE % was determined indirectly for NAC; NP suspension was purified by centrifugation 
at 14000 rpm for 30 min.  Un-encapsulated drug was quantified in the supernatant and 
accordingly the amount of encapsulated drug determined using equation 1.  
    
                            
                   
                                    (1) 
On the other hand, FL EE % was determined directly where the centrifuged pellet was 
reconstituted in 1 ml of DI water. EE% was determined based on FL fluorescence using 
microplate fluorometer (λex= 490 nm, λem= 519 nm). For NAC, Ellman’s reagent (also 
known as DTNB) was used for quantification. DTNB is a water-soluble compound for 
quantitating free sulfhydryl groups in solution. DTNB reacts with a free sulfhydryl group to 
yield a mixed disulfide and 2-nitro-5-thiobenzoic acid (TNB). TNB is colored and has a 
high molar extinction coefficient in the visible range [79]. Accordingly absorbance of the 
resultant TNB at λ= 412 nm could be used to quantify NAC based on its sulfhydryl content 
(Figure 7). 
To determine un-encapsulated and encapsulated concentration of NAC and FL; 
respectively, a calibration curve was constructed using standard solutions prepared in DI 
water (for NAC: 0.30, 0.25, 0.20, 0.15, 0.10, 0.050, 0.030, 0.020, 0.015, 0.010 mg/ml and 
for FL: 0.028, 0.020, 0.010, 0.005, 0.003, 0.002, 0.001, 0.0005 mg/ml). For NAC, DTNB 
reaction protocol was optimized for use in 96-well U-bottom microplate. In each well, 27 µl 
of sample or standard solution were added to mixture of 268 µl reaction buffer (0.1 M 
sodium phosphate, pH 8.0, containing 1 mM EDTA) and 6 µl DTNB. Absorbance was 
measured at λ= 412 nm for both samples and standards. For FL, fluorescence of 50 µl of 
standard solutions and samples were measured using the microplate fluorometer (FLUOstar 
Optima Microplate Fluorometer, BMG LABTECH, Ortenberg, Germany) and 96-well clear, 
F-bottom half-area black microplate at λex= 490 nm and λem= 519 nm. Sample concentration 
was calculated from the corresponding standard curve.  
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As for cisplatin (Figure 8), stock solution (2 mg/ml) was prepared in DI water. 200 µl of 
stock solution were added to 2 ml of 0.1 % TPP solution (pH 5). Then to 5 ml 0.1% CS 
solution (pH 5) cisplatin-containing TPP solution was added all at once and the mixture was 
stirred for 30 min using magnetic stirrer at 400 rpm at room temperature to obtain cisplatin-
loaded CS NPs and CS-MNPs respectively. Afterwards, the mixture was centrifuged for 30 
min at 14000 rpm and EE % of cisplatin was determined indirectly similar to NAC. 
Absorbance of un-encapsulated cisplatin was determined using Flame Atomic Absorption 
Spectrometer (FAAS) (240 AA, Agilent Technologies Inc., CA, USA) with the aid of 
platinum standard curve prepared in DI water (5, 20, 40, 60, and 80 mg/L) at λ=265.9 nm. 
Triplicates for each type of NP were analyzed and the arithmetic mean for each triplicate 
was adopted to ensure EE % reproducibility. 
2.2.2. Determining the effect of drug encapsulation on the physicochemical 
properties of CS NPs: 
The effect of drug encapsulation on the CS NPs size and surface charge was evaluated. 
FE-SEM was used to evaluate the drug-loaded CS NPs morphology. DLS and LDE were 
used to determine size and surface charge of drug-loaded CS NPs respectively. Samples for 
FE-SEM, DLS and LDE were prepared similar to CS NPs samples mentioned before. 
Triplicates for optimum drug-loaded CS NPs were analyzed for size and surface charge. The 
arithmetic mean value of the three was adopted. 
2.2.3. Determination of MNPs encapsulation’s effect on drug-loaded CS NPs 
size, surface charge and EE %: 
0.5 mg of MNPs were added to 5 ml drug-containing 0.1 % CS solution (pH 5) (this is 
incase of NAC and FL, but for Cisplatin it is dissolved in TPP). 2 ml of 0.1 % TPP solution 
(pH 5) were added directly to the CS solution containing MNPs. The mixture was stirred for 
30 min at 400 rpm at room temperature. Triplicate for the sample was analyzed and the S.D. 
and arithmetic mean were adopted to ensure formulation’s EE % reproducibility. For 
obtained NPs hydrodynamic size and zeta potential were examined using DLS and LDE; 
respectively as detailed earlier. For DLS and LDE samples were analyzed in triplicates and 
results were presented as mean ± S.D. 
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2.3. Drug Release: 
2.3.1. Determination of drug release profile from drug-loaded NPs: 
NAC and FL release rate from NPs was determined. NPs were purified and re-
suspended in 1 ml DI water. Purified NPs were placed inside spectra/por float-a-lyzers 
(MWCO=100 KDa). Float-a-lyzers were soaked in 6 ml PBS maintained at 37 °C while 
shaking at 100 rpm (Figure 9), at assigned time intervals (0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 
120, 144 and 168 hrs) aliquots were withdrawn from the release compartment and analyzed 
for the released drug. For NAC, Ellman’s reagent was used and for FL fluorescence was 
determined directly using fluorometery. However, to avoid fluorescence of released FL 
being lower than the minimum detection limit of device, two batches of FL-loaded NPs 
were re-suspended in 1 ml DI water and placed in a float-a-lyzer.  The same amount of free 
NAC and FL were dissolved in 1 ml DI water and placed in float-a-lyzers as controls and 
analyzed similarly to their corresponding samples. Duplicates of sample and control were 
run together and results were presented as mean ± standard deviation (S.D).   
2.3.2. Determination of MNPs effect on drug release upon the application of 
high frequency magnetic field (HFMF): 
MNPs and FL-loaded CS NPs (FL-loaded CS-MNPs) were used to determine the effect 
of magnetic field application on drug release profile in comparison to FL-loaded CS NPs. 
0.5 mg of MNPs were added to 5 ml of FL-containing 0.1 % CS solution (pH 5). To FL-
containing CS solution 2 ml of 0.1 % TPP solution (pH 5) were added all at once and the 
mixture was stirred for 30 min at 400 rpm at room temperature.  
In preliminary experiments, it was found that the temperature in the samples (measured 
using an Opsens IR-sensor OTG-A-62), independent from its composition, levels quickly to 
about 32 °C under the HFMF treatment employed. For comparison reasons, the release 
profiles of the samples were compared under a constant temperature of 32 °C (thermostat) 
and under the periodic influence of a HFMF. Each experiment was carried out twice in 
order to ensure reproducibility. 
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1
st
 Experiment: Release profiles at 32°C (without HFMF): 
500 μl of FL-loaded samples (CS NPs and CS-MNPs) were put in the sample holder of 
the float-a-lyzer. The exterior was filled with 6 ml of PBS solution, and the temperature of 
water bath was adjusted at 32 °C in which the float-a-lyzer was placed. Ever 20 min, 
samples were taken from the buffer reservoir, and employed for the fluorescence 
measurement after 1:1 dilution with PBS. This procedure was repeated over a period of 8 
hours. 
 
2
nd
 Experiment: Release profiles under influence of HFMF: 
The magnetic heating experiments were performed using a high frequency (HF) 
induction generator (AIXO T5, Hüttinger Electronic Inc., GmbH, Freiberg, Germany) at f = 
273 kHz and a power of 5.0 kW, using a water cooled copper induction coil with 5 winds, 
an inner diameter of 35 mm and a length of 50 mm. Similar procedure was performed as in 
the 1
st
 experiment, but this time float-a-lyzers were placed inside the induction coil to be 
exposed to alternating magnetic field (AMF). Magnetic field was switched on for 10 min, 
and paused for 10 min in order to prevent overheating of the sample. After this period of 20 
min, samples were taken from the buffer reservoir, and employed for the fluorescence 
measurement after 1:1 dilution with PBS. Similarly this procedure was repeated over a 
period of 8 hours. 
Normalized FL concentration (Cfl/Cfl, theo) was used to represent the release rate, where 
the theoretical FL concentration (Cfl, theo) is the theoretical fluorescence concentration at 
equilibrium, i.e. assuming all FL of the sample as obtained from the initial concentration 
measurement (FL Cfl, 0) was isotropically distributed throughout the sample. For each time 
point, Cfl, theo is thus accessible by equation 2. 
          
   
      
 
        
         
         (2) 
With nfl: molar amount of FL present in the system, Vtotal: total volume in the system. 
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V0: sample volume placed in the inner sample holder of the float-a-lyzer, Vb: buffer 
volume in the reservoir, N: number of aliquots taken at the present data point, Vs: volume 
of the aliquot replaced. 
 
For the determination of the time constant τ; characteristic for the respective release rate, 
equation 3 was applied. 
 
                
  
                        (3) 
With t: release time. This can be linearized to: 
 
   
            
        
  
 
 
        (4) 
By plotting the logarithmic term against time, τ was determined for the respective 
system. 
2.4. NPs modification: 
2.4.1. Tagging of EGFR-antibody to CS NPs surface: 
CS-NPs and CS-MNPs (MNPs-loaded CS NPs) were initially tagged with IgG-FITC 
antibody to easily quantify the amount of antibody attached to NPs via fluorometery. To tag 
an antibody to CS, 1-ethyl-3-(3-dimethylaminoisopropyl) carbodiimide (EDC) was used. 
EDC is a an amine-COOH cross linker that is used to create covalent links between CS NPs 
amine- and IgG’s carboxyl groups as shown by Figure 10. 
From initial IgG-FITC stock (10-20mg/ml), 2 ml of 1mg/ml IgG-FITC were prepared in 
cold DI water (4°C). EDC (1 mg/ml) was also prepared in cold DI water (4°C). To an 
eppendorf tube 0.25 ml of 1mg/ml IgG-FITC was added; to which 10 µl of 1mg/ml EDC 
were added. The mixture was vortexed (Vortex V1 plus, BOECO, Hamburg, Germany) for 
1 min at maximum speed. Then 0.75 ml of either CS-NPs or CS-MNPs were added directly 
to the mixture. Finally, the whole mixture was shaken for 3 hours at room temperature. 
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2.4.2. Quantification of tagged EGFR-antibody: 
The conjugated antibodies were quantified using fluorometery. Serial dilutions in DI 
water (0.1, 0.05, 0.03, 0.01, 0.005 & 0.0025 mg/ml) were used to construct a calibration 
curve. IgG-FITC tagged CS NPs and CS-MNPs were centrifuged at 14000 rpm for 30 min, 
supernatant was discarded and pellet was re-suspended in the same initial volume. FITC 
emission of re-suspended pellets is measured and tagged IgG were quantified accordingly. 
For each sample triplicates were analyzed and the arithmetic mean was adopted to validate 
reproducibility of tagging technique. 
2.5. NPs-cell interaction: 
2.5.1. Cellular cultivation: 
A549 and L929 cells were cultivated in phenol red free RPMI 1640 with L-Glutamine 
media supplemented with 10 % FBS and 1 % Pen-Strep antibiotic in 5 % CO2-incubator 
(AutoFlow NU-5510 Direct Heat CO2 Incubator, NuAire, SC, USA) at 37°C. 
2.5.2. Extent of NP uptake determination; effect of NP: 
2.5.2.1. MTT assay: 
For MTT toxicity assay, A549 and L929 cells were plated in separate 96-well F-bottom 
cell culture plates. For both types of cells 20x10
3
 cells/ well were plated. Different 
concentrations of CS NPs (250, 500, 1000 & 2000 µg/ml), CS-MNPs (250, 500, 1000 & 
2000 µg/ml) and MNPs (25, 50, 100 & 200 µg/ml) were added. Quintuplets were assigned 
for each NP concentration and the arithmetic mean was eventually adopted. Untreated cells 
were used as controls and absorbance values at λ= 570 nm for those cells were considered 
as 100 % viability. Cells were incubated with particles for 24 hrs. Following incubation, 
cells were washed with PBS and MTT of concentration 0.5 mg/ml was added and followed 
by 2 hrs of incubation. MTT was then replaced with DMSO and the plate was thoroughly 
mixed in a shaking incubator for 1 hr. Finally, absorbance of wells was measured using 
microplate fluorometer at λ= 570 nm. Cell viability for each NP concentration was then 
determined relative to control.  
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2.5.2.2. Effect of NPs concentration and modification on the cells’ uptake 
magnitude: 
Tagged and non-tagged CS NPs and CS-MNPs loaded with FL were used to study NP 
cellular uptake in A549 cells. EGFR-antibodies were used to tag FL-loaded CS NPs and 
CS-MNPs. To one batch of NPs re-suspended in 0.5 ml of DI water, 30 µl of EGFR-
antibody (equivalent to 30 µg/ml) were added to cells. Simultaneously, non-tagged NPs 
were prepared. Both tagged and non-tagged NPs were used to determine the uptake of A549 
cells. For this purpose cells were seeded at a density of 10
5
 cells/well. Different 
concentrations of tagged and non-tagged CS NPs and CS-MNPs (150 & 250 µg/ml) were 
added to A549 cells and incubated for 24 hrs. After 24 hrs, cells were washed with PBS. 
Amount of uptaken NPs were determined by fluorometery (λex: 495 nm and λem: 519 nm) 
with the help of a NP calibration curve in DI water (CS NPs and CS-MNPs in PBS: 0.1, 0.5, 
1.0, 3.0, 5.0, 7.0, 10.0, 15.0, 20.0 & 25.0 µg/ml). 
2.5.2.3. NPs Uptake confirmation by CLSM: 
In 6-well F-bottom plate 10
5
 cells/ well were seeded on coverslips. For cellular uptake, 
400 µg/ml of purified FL-loaded CS NPs were added to well. Cells were incubated for 24 
hrs. After incubation, cells were washed with PBS then 1 ml of 1 µl/ml Hoechst (λex: 352 
nm and λem: 461 nm) was added to each well and incubated in the dark for 15 min at room 
temperature. Cells were then washed twice with PBS.  Subsequently, 1 ml of 15 µg/ml 
WGA-AF (λex: 495 nm and λem: 519 nm) was added and cells were incubated for 5 min at 
4°C in the dark. Cells were then washed twice with PBS and fixed with ice cold methanol at 
-20°C for 15 min. Finally, the coverslips are flipped on clean glass slides after being washed 
with PBS. Glass slides were incubated at 4°C overnight then was examined using Confocal 
Laser Scanning Microscopes (CLSM), (710, ZEISS, Jena, Germany).  
2.5.3. Efficiency of Cisplatin-loaded NPs via MTT assay: 
After determining encapsulated amount of cisplatin in both types of NPs, un-modified 
NPs were prepared. MTT assay was conducted as previously detailed (section 2.5.2.1), to 
determine the effect of cisplatin-loaded NPs on cell viability. Different concentrations of 
cisplatin (10 & 40 µg/ml) encapsulated in CS NPs and CS-MNPs were added. Free cisplatin 
in DI water was assigned as control to evaluate loading of cisplatin into NPs. Percentage of 
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cisplatin that should have been released supposedly for both NPs after 24 hrs (which was 
higher than the minimum effective concentration of cisplatin (1 µg/ml) for all 
concentrations and NPs added) was added from cisplatin stock solution to determine the 
efficacy of amount released. Quadruplicates of each cisplatin concentration were analyzed 
and the arithmetic mean and S.D. of each quadruplicate were adopted. 
2.6. Spray freeze drying (SFD) and evaluation of Lung deposition by next 
generation impactor (NGI): 
2.6.1. Incorporation of NPs in Polyvinylpyrrolidone (PVP): Maltodextrin (MD) 
microparticles (MPs): 
CS NPs and CS-MNPs were formulated and suspensions were SFD in the presence of 
cryopreservatives (5% (w/v) of 1:1 mixture of PVP: MD). The use of PVP:MD mixture was 
the most suitable for CS NPs encapsulation with the absence of aggregation based on 
several trials. SFD is a three step process: droplet formation, freezing, and freeze drying 
[80], Figure 11 provides a description of the SFD device.  For droplet formation, a drop jet 
nozzle (2 fluid nozzle, Microdrop Technologies GmbH, Norderstedt, Germany) with a 
nozzle diameter of 0.5 mm was placed at the top of the spray tower.  To adjust the 
stimulation frequency of the drop jet nozzle a control panel was used, by pressurized air the 
feed solution (FL-loaded CS NPs and CS-MNPs suspensions) is transported to the nozzle. 
The jet was adjusted at an approximate velocity of 10 m/s, where a constant Rayleigh drop 
dispersion was achieved after leaving the nozzle, stimulated by a piezoelectric pulse. Within 
a cooled, stainless steel spray tower encased by liquid nitrogen-containing cooling jacket, 
the freezing process was performed. To avoid cooling losses, the cooling chamber was 
heavily insulated. In operation, the system was cooled to temperatures below −90 °C. 
Particles froze instantaneously within the tower. They were then collected in a cooled and 
isolated beaker at the bottom of the tower. Then the frozen particles were transferred into a 
freeze dryer and subsequently dried under a vacuum for at least 36 h. Following SFD, NPs 
were reconstituted in de-ionized water and NP size and morphology was determined using 
SEM. 
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2.6.2. Evaluation of aerodynamic properties of MPs using NGI: 
The aerodynamic properties of the prepared powders were determined using a Next 
Generation Impactor (NGI) (Copley Scientific. Nottingham, UK) (Figure 12). When 
vacuum is turned on, particles flow with the air stream passing by eight consecutive stages 
where they will impact based on their aerodynamic size cutoffs. Attached to the NGI was 
the HandiHaler DPI device (Boehringer Ingelheim, Germany) via a mouthpiece adaptor. All 
stages before each run were coated with 1% w/v silicon oil in n-hexane to reduce bouncing 
of particles between stages. Manually five capsules (size 3) were filled with 5–7 mg 
powder. They were discharged into the NGI into the DPI. The airflow rate was adjusted to 
45 L/min for 5.3 s with the aid of a critical flow controller (Copley Scientific, UK); to 
mimic 4 L of air drawn per breath in human inhalation. For stages 1-7, the effective cut-off 
aerodynamic diameters for each stage are 9.1, 5.2, 3.3, 1.9, 1.1, 0.6, and 0.4 µm; 
respectively at rate of 45 L/min. The contents of the following; capsules, DPI, mouthpiece 
adaptor, induction port, pre-separator, stages 1–7 and the micro-orifice contactor (MOC) 
after operation were washed with DI water into volumetric flasks and volume was adjusted. 
Spectrophotometrically the fluorescence intensities of the solutions were measured (λes: 485 
nm and λem: 535 nm) using Multilabel counter (Wallac 1420 Victor3, PerkinElmer). Each 
powder was tested and analyzed in triplicate. Using data analysis the recovered dose (RD; 
all powder collected starting from the capsules to the MOC), the emitted fraction (EF; the 
powder fraction that left the inhaler with respect to the recovered dose) and the fine particle 
fraction (FPF; fraction of the recovered dose with cut-off AD ≤ 5.2 µm) were calculated. 
Cumulative percentage undersize was plotted versus effective cut-off diameter. From this 
plot the mass median aerodynamic diameter (MMAD) was determined. 
2.7. Statistical analysis: 
Statistical analysis of data was performed with one-way analysis of variance (ANOVA) 
using Design-Expert® Software (Stat-Ease, Inc., USA). P-values less than 0.05 were 
considered significant.
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Chapter 3: Results 
1. NPs formulation and characterization: 
1.1. CS NPs: 
1.1.1. Morphology and size: 
CS NPs synthesized with various parameters have developed three types of particles: 
microparticles, aggregates and small NPs (Figure 13 and Table 2) via SEM measurement. 
After SEM examination it seemed that formulas 9-11 fall in the desired size range, and were 
therefore subjected to further analysis. DLS was used for further analysis of formulas 9-11 
for size and size distribution. Results are summarized in Table 3. The smallest diameter was 
provided by formula 11, thus it was considered as the optimal. Two more samples of 
formula 11 were prepared and analyzed with DLS to confirm formula’s reproducibility. The 
mean size for CS NPs was determined to be 63.0±3.0 nm. In concurrence with SEM and 
DLS, AFM was used to confirm formula 11 as being the most suitable formulation by 
possessing smallest size as presented by Figure 14.  
1.1.2. Surface charge measurement with LDE: 
Zeta Potential was determined for three different samples of formula 11 by LDE 
technique. The obtained CS NPs showed surface charge of 28.6± 0.6 mV. This indicates 
that CS NPs were positively charged thus, ensuring formula 11 as the optimal with smallest 
size and relatively high positive charge. 
2.  MNPs: 
Among various formulations prepared with varying parameters, only some of the 
developed MNPs were attracted to magnet when applied across the vial externally. Results 
are summarized in Table 4. 
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2.1. Morphology, size and surface charge: 
2.1.1. DLS and LDE Measurement: 
DLS and LDE were used to determine the size and surface charge respectively of MNPs 
synthesized with varied parameters. Results are summarized in Table 5. Formula 8 has 
provided the smallest diameter with highest surface charge, thus was considered as the 
optimal. Two more samples of formula 8 were prepared and analyzed with DLS and LDE to 
confirm formula’s reproducibility. The mean size and surface charge for MNPs were 
27.4±2.8 nm and -26.6 ± 4.6 mV; respectively. 
2.1.2. STEM Measurement: 
Further characterization was performed for formula 8 using STEM to determine the 
actual size for the synthesized MNPs rather than the hydrodynamic diameter provided by 
the DLS. This is to ensure that the particles obtained are superparamagnetic since these 
nanoparticles should be ≤ 20 nm. The actual size of formula 8 MNPs is shown in Figure 15 
to be 5.5±0.7 nm. This indicates that obtained MNPs are USPIONs. 
2.2. Functional groups determination with FT-IR: 
The functional groups of obtained MNPs for formula 8 were examined using FT-IR 
(Figure 16). The functional groups of MNPs are represented in Figure 16(a), while the 
relationship of these functional groups to precursors from which MNPs are synthesized 
(FeCl3.6H2O and Vit C) is shown in Figure 16(b). 
The chemical transformation of FeCl3.6H2O and Vit C into iron oxide NPs capped with 
dehydroascorbic acid (DHAA) has been analyzed by FT-IR. In Figure 16b the 
characteristic absorption bands for stretching C=O of the five membered lactone ring of Vit 
C were shown at 1755 cm
-1
 and stretching vibrations of C=C coupled with neighbouring 
vibrations were visualized at 1656 cm
-1
 [81-82]. In Figure 16a the strong band visualized at 
553 cm
-1 
in the spectrum of the prepared MNPs is due to the Fe-O vibrations characteristic 
for iron oxide NPs. However, the stretching C=O bands in Vit C were absent in the prepared 
MNPs, indicating the presence of a coordination bond between the carbonyl group’s O atom 
and the Fe center on the surface of NPs [83-85]. The presence of new absorption band at 
1611 cm
-1 
confirmed the coordination. The bands at 1356, and 1048, 1100 cm
-1
 are assigned 
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to the C-O and C-O-C stretches of the lactone ring [82] in the as-prepared γ-Fe2O3-DHAA 
conjugate, suggesting that no interaction is taking place between lactone ring O atoms and 
the NPs. Moreover, the presence of hydroxyl groups on the surface of the prepared MNPs 
was confirmed by the strong OH stretching mode at 3241 cm
-1
. 
2.3. Magnetic properties measurement using VSM: 
VSM was used to determine the magnetic properties of synthesized MNPs (formula 8). 
As shown by Figure 17, the hysteresis loop of MNPs is sigmoid in shape with negligible 
hysteresis. The VSM chart (Figure 17) showed that these MNPs present magnetic 
saturation (Ms), coercivity (Hc) and retentivity (Mr) of 48.4 Am
2
/Kg,  9.9x10
-4
 T and 0.5 
Am
2
/Kg; respectively. 
2.4. Determination of MNPs crystallography using XRD: 
XRD was used to determine the crystal structure of MNPs (formula 8) as shown in 
Figure 18. Peaks provided were related to cubic γ-Fe2O3 (JCPDS-ICDD Card No. 24-
0081). 
3. Void CS-MNPs: 
3.1. Morphology, size and surface charge: 
3.1.1. DLS and LDE Measurement: 
Formula 1 (CS-MNPs) possessed a size and surface charge of 104.3±9.9 nm and 
40.8±0.2 mV; respectively. For the aim of obtaining better drug release upon the application 
of alternating magnetic field (AMF), the encapsulation of more MNPs was tried. Thus, 1 
and 2 mg of MNPs were incorporated into CS-NPs. Both formulas showed aggregation and 
irreproducibility in synthesis with regards to size. This aggregation was significantly 
visualized for formula 3. Thus, these formulas were excluded. 
3.1.2. HR-TEM: 
Characterization of formula 1 (CS-MNPs) using HR-TEM was performed to ensure 
MNPs encapsulation within the CS NPs with the preservation of the spherical morphology. 
Figure 19 showed that each CS NP was encapsulating several MNPs, providing CS NPs 
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with homogeneously dispersed magnetic multi-cores.  Obtained CS-MNPs were spherical in 
shape. 
4. Drug loading and its effect on NPs physicochemical properties: 
4.1. Determining the effect of drug encapsulation on the physicochemical 
properties of CS NPs: 
4.1.1. EE % of CS NPs: 
CS NPs zeta potential and size were assessed after drug incorporation to evaluate the 
drug’s influence on NPs physicochemical properties. For NAC, different concentrations 
were used to determine NPs EE% and encapsulation reproducibility. NAC concentration of 
10 mg/ml has provided the most reproducible EE% (Table 6). Thus, this concentration was 
used later for evaluation of drug release profile of CS NPs. 
For FL and Cisplatin, NPs entrapped the following concentrations: 23.9±1.1 and 
498.02±0.002 µg/ml; respectively. 
4.1.2. Morphology, size and surface charge: 
Size of NPs after drug incorporation was measured using DLS. Fortunately, no 
significant alteration of size was visualized for added concentrations of drugs (63.4±6.5 nm, 
60.4±2.4 nm and 62.5±7.8 nm, for AC, FL and Cisplatin; respectively). To further confirm 
NP formation in the presence of drug, drug-loaded CS NPs were analyzed by SEM (Figure 
20). SEM image showed that NPs preserved their spherical morphology with same size 
range as void CS NPs.  
4.2. Determination of MNPs encapsulation’s effect on drug-loaded CS NPs 
size, surface charge and EE %: 
Using Formula 1, the incorporation of MNPs reduced the amount of entrapped drugs in 
CS NPs to 29.7±1.6 %, 13.0±0.1 and 412.2±0.0008 µg/ml for NAC, FL and Cisplatin; 
respectively. The incorporation of MNPs also have resulted in the increase of hydrodynamic 
size of NAC, FL and cisplatin-loaded CS-MNPs significantly by 1.5-2 folds (93.6±4.0, 
122.4±0.0, 128.8±1.5 nm; respectively) (un-paired t-test).   
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5. Drug Release: 
5.1.Determination of drug release profile from drug-loaded CS NPs: 
Release profile of CS NPs was determined for NAC versus control of free NAC as 
shown in Figure 21. Free NAC has shown to provide higher release rate than CS NPs, but 
the release profile was rather erratic and not reproducible. The reason for such unexpected 
results was attributed to the nature of NAC quantification as will be discussed in Chapter 
4-section 2.1. Further experiments with NAC loaded NPs were therefore halted and only 
FL-loaded CS NPs were used for further evaluation of NPs release profile. 
5.2.Determination of drug release profile from drug-loaded CS NPs and CS-
MNPs: 
Figure 22 shows the FL release profile from FL loaded NPs.  Only 5 and 25 % of FL 
was released from CS NPs and CS-MNPs; respectively after 168 hrs compared to the 
control that provided 100 % release during the same period. By visualizing the obtained 
chart, for CS-NPs an initial burst of FL is seen where 2 % is released in 1 hour followed by 
a slow, steady increase in the percent of FL released from NPs. For CS-MNPs the initial 
burst is absent. The percentage of FL released from CS-MNPs was significantly higher than 
that of CS NPs. 
5.3.Determination of MNPs effect on drug release upon the application of 
HFMF: 
For FL-loaded CS NPs and CS-MNPs, release profile with and without HFMF 
application was performed. From Figure 23 it can be visualized that there is significant 
difference in the rate of release for FL-loaded CS-MNPs upon the application of AMF. 
From the constructed logarithmic charts, τ was obtained for both types of NPs either 
exposed or non-exposed to HFMF (Figure 24).τ values for CS NPs in the absence and 
presence of HFMF were not significantly different (917±77 and 762±83 min without, and 
with HFMF application; respectively (P>0.05, n=3)). As for CS-MNPs τ values were rather 
significantly different (258±11 and 150±14 min, without and with HFMF application; 
respectively (P<0.001, n=3)) indicating that a stimulus responsive release is only seen in 
CS-MNPs.  
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6. Quantification of EGFR-antibody used to modify the surface of drug and 
MNP-loaded CS NPs: 
Figure 25 shows the IgG-FITC calibration curve from 0.05mg/ml to 0.0025mg/ml. From 
the curve equation the concentration of tagged IgG-FITC was determined for CS NPs and 
CS-MNPs. Using this curve’s equation concentration of tagged IgG-FITC was 0.024±0.002 
and 0.018±0.001 mg/ml for CS NPs and CS-MNPs; respectively.  
7. NPs-cell interaction: 
7.1.Extent of NP uptake determination; effect of NP: 
7.1.1. MTT assay: 
The cytotoxicity of CS NPs, CS-MNPs and MNPs were evaluated for A549 and L929 
cell lines using MTT assay as shown in Figure 26. From Figure 26 it can be seen that at 
high concentrations for CS NPs and CS-MNPs (2000 µg/ml) preferential cytotoxicity 
towards cancer cells is observed. Whereas, at high concentration of MNPs (200 µg/ml) 
cytotoxicity was visualized on both cell lines.  
7.1.2. Effect of NPs concentration and modification on the cell’s uptake 
magnitude: 
After tagging NPs with EGFR-antibody, the cellular uptake of tagged and non-tagged 
NPs were evaluated using A549 cell lines as represented by Figure 27. From the chart it can 
be determined that the cellular uptake increased with increased NPs concentration while 
modification of NPs with ABs has lowered the cellular uptake significantly.  
7.1.3. NPs Uptake confirmation by CLSM: 
By the aid of CLSM the uptake of FL-loaded CS NPs by A549 cell lines were confirmed. 
Figure 28 represents CLSM images of A549 cell lines in which Figure 28(a) shows 
untreated cells. Red fluorescence is attributed to labeling with WGA-AF, which in the 
absence of CS-NPs labels cell membranes and some organelles. Figure 28(b) shows NP 
treated cells; green FL is attributed to FL loaded NPs, which appear to be inside the cell in 
the perinulclear area. Figure 28(c) shows overlap of red (WGA-AF) and green (FL) 
fluorescence. Since WGA-AF and FL-CS-NPs are co-localized this indicates that green FL 
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seen in Figure 27 (b) is in fact owed to NPs rather than noise or released FL since WGA 
shows preferential affinity to chitosan. 
7.1.4. Efficiency of Cisplatin-loaded NPs via MTT assay: 
MTT assay was used to determine cisplatin efficacy on A549 cells after being 
encapsulated in developed NPs (Figure 29). For free cisplatin it can be visualized that 
increasing the concentration of drug, cell viability is significantly lowered. As for CS-
loaded cisplatin decrease in cell viability is not significantly different from void NPs.  
8. SFD and evaluation of Lung deposition by NGI: 
8.1.Incorporation of NPs in PVP: MD MPs: 
After SFD, MPs were examined by SEM (Figure 30). As seen, MPs obtained for both 
types of NPs are spherical in shape and nearly of the same size ~ 3 µm. 
8.2.Evaluation of aerodynamic properties of MPs using NGI: 
Figure 31 shows the NGI dispersion results for CS NPs and CS-MNPs.  For both NPs, a 
very small amount seems to be retained in the capsule and similarly in the mouth as 
indicated by amount in capsules in mouth piece. Inhaled percentage of dose (passed the 
throat) is ~37 % for both NPs. However, ~50 % were deposited past the trachea. Both types 
of particles have also possessed fine particle fraction (FPF≤ 5.2 µm) of ~40 % indicating 
successful delivery to deep lung tissue. Processing the NGI data also allowed the 
determination of the MMAD which corresponded to 6.1 µm for CS-MNPs and 5.1 µm for 
CS NPs.
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Chapter 4: Discussion 
1. NP formulation and characterization: 
1.1. CS NPs: 
CS NPs synthesis was performed via ionotropic gelation process. This procedure is very 
mild; devoid of the usage of organic solvents (which are crucial to the popular emulsion 
based NP formulation methods). The method involves the addition, of alkaline TPP solution 
(pH=7–9) onto an acidic CS solution (pH=4–6). NPs are formed instantaneously upon 
mixing of the two phases through intra and intermolecular crosslinking between TPP 
negatively charged phosphate and CS positively charged amino groups (Figure 32). By 
varying concentrations, pH and added volumes of CS and TPP, NPs with varying 
characteristics can be obtained [86]. 
While formulating the NPs, the aim was to obtain NPs optimal for cell uptake; positively 
charged and less than 150 nm in diameter. Positively charged NPs are attracted to the 
negative cell surface enhancing cellular entry by endocytosis [87]. Studies have also showed 
that smaller NPs (less than 150 nm) show higher cell uptake than larger ones [88]. Since CS 
NPs will later encapsulate drug and MNPs which may possibly lead to an increase in 
particle size, therefore the optimal formula should initially have the smallest size. To do so 
varying formulation parameters were initially tried out to reach NPs with optimal 
characteristics and initial assessment was based on visual observations, where opalescent 
samples were regarded as colloidal suspensions and subjected to further examination by 
SEM visualization. Table 2 summarizes the results. 
1.2. MNPs: 
While formulating the MNPs the aim was to obtain biocompatible MNPs that are 
negatively charged and 5 nm in diameter or less. Negatively charged MNPs were preferred 
to be easily encapsulated within positively charged CS NPs through electrostatic interaction. 
Small sized MNPs (less than or equal 5 nm i.e. USPIONs), ensure absence of aggregation 
upon the removal of external magnetic field [89-91], to avoid blockage of vascular system 
and toxicity due to aggregation within a tissue or organ. 
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MNPs were prepared via hydrothermal method in which Vit C acted as both reducing 
and capping agent for the resulting NPs. This redox reaction allowed synthesis of NPs to be 
performed in one step in the absence of any organic solvents [92]. 
Different formulations were tried out with varying formulation parameters to reach NPs 
with optimal characteristics. Initial assessment was performed by DLS for formulations 
summarized in Table 5 (i.e. those showed magnetic attraction to externally applied magnet). 
Analysis by SEM was difficult due to particles’ agglomeration on silicon wafer as a result 
of Van der Waal forces between them [93]. In addition to the difficulty of identifying the 
size of individual particles due to inability of imaging using high magnification to prevent 
detector damage. SEM imaging is based on the transmission of electron beam to the 
specimen’s surface to provide a topological image for the specimen’s surface. To focus the 
beam of electrons on the examined specimen electromagnetic lenses are used. To obtain 
high resolution image in-lens detectors are preferred to focus the back scattered electrons. 
The presence of this high magnetic field results in the magnetization of MNPs accelerating 
them towards the detector. Thus, other than distorting the obtained images, detector 
malfunctioning may result especially at high magnification since the magnetic field will 
increase as more focusing will be required [94-95]. LDE measurement was performed to 
assess MNPs stability based on their surface charge.   
The average hydrodynamic size of MNPs is provided by DLS, actual core size was 
determined using both XRD and STEM. Assessment of MNPs (formula 8) with XRD 
confirmed the production of cubic γ-Fe2O3 (JCPDS-ICDD Card No. 24-0081). Using 
Debye-Scherrer formula (represented as equation 5), the average crystallite size of the 
individual maghemite NPs was calculated to be 5.6 nm from XRD peak broadening.  
  
  
     
                      (5) 
With K: shape factor of value of 0.9, λ: x-ray wavelength, β: line broadening at half the 
maximum intensity and θ: Bragg angle. 
STEM confirmed that spherical NPs with homogenous size distribution of an average 
size of 5.5±0.7 nm is achieved (Figure 15). This size is harmonious with the crystallite size, 
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calculated from the XRD data.  The formation of NPs was also confirmed by FT-IR (Figure 
16). FT-IR also proved the presence of terminal hydroxyl groups as indicated by the strong 
OH stretching at 3241 cm
-1 
[92]. These terminal hydroxyls explain why the overall MNP 
charge is negative and are quiet favorable as they increase the MNPs water dispersibility 
and may serve as potential for further functionalization for the intended biomedical 
application.   
The magnetic properties of prepared iron oxide NPs were measured using VSM at room 
temperature with magnetic field of 3.1 T. The synthesized MNPs magnetic properties were 
all of comparable values to previously synthesized iron oxide NPs in accordance with their 
size [91, 96-97]. Low coercivity and remanence values indicate that MNPs possess 
superparamagnetic behavior. Thus, complications that may result from agglomeration of 
MNPs after withdrawal of externally applied magnetic field will be avoided [98]. 
1.3. Void CS-MNPs: 
Several amounts of MNPs were added to CS. However with amounts larger than 0.5mg 
aggregation was observed. The latter could be attributed to increased NPs size 
simultaneously with increased MNPs encapsulation, this is due to interference of negatively 
charged MNPs with TPP-CS crosslinking; weakening it resulting in aggregate formation 
[99]. 
2. Drug loading and its effect on NPs physicochemical properties: 
2.1. Determining the effect of drug encapsulation on the physicochemical 
properties of CS NPs: 
Since NAC and FL are negatively charged at pH 5, they will electrostatically interact 
with positively charged CS [100-101].  Thus, during drug-loaded CS NPs synthesis, both 
types of drug were first added to CS before NP formation. For NAC, when EE% for NPs 
prepared with 12 and 7 mg/ml were compared to the initial batches prepared with 10mg/ml, 
changes in EE% were not statistically significant (unpaired t test). However synthesis with 
10mg/ml showed highest reproducibility and therefore further tests were conducted with NP 
batches prepared with 10 mg/ml NAC. 
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The CS NPs showed an EE% of 41% for 10 mg/ml added NAC using Ellman’s reagent. 
Although 41% seems to be small, for a small molecule (low molecular weight) such as NAC 
in NPs of such size is acceptable [102-104]. CS NPs are hydrogel NPs where drugs are 
encapsulated into their matrix and may exit by diffusion. Diffusion rates are generally 
higher for smaller molecules than for proteins and other macromolecules, for such reason 
higher EE% is seen for larger molecules while lower EE% for smaller ones as seen in Table 
7. Moreover EE% increases with the increase in NP size, however a smaller size allows for 
better cell uptake. Since formulated NPs were prepared for drug delivery purpose into 
cancer cells, compromising cell uptake by increasing EE% at the expense of NP size was 
not desirable, especially that CS-NPs do not exhibit toxic effects on non-cancer cells at very 
high concentrations (up to 2 mg/ml) and therefore a larger concentration of NPs could 
always be used to compensate for the rather low EE%. 
2.2. Determination of MNPs encapsulation’s effect on CS NPs size, surface 
charge, morphology and drug loading: 
Negatively charged MNPs were added to CS solution with NAC or FL during synthesis 
to electrostatically interact with positively charged amino groups of CS before the addition 
of TPP. The addition of 0.5 mg MNPs provided NPs with good dispersibility, but resulted in 
the entrapment of 30% of the drug instead of 40% obtained with void CS NPs. This is 
considered to be normal since the MNPs have displaced some drug molecules as both are 
aiming to form electrostatic bonds with positively charged amine groups of CS. This 
competition resulted in the decrease of loaded drug by almost 10% and increase of NPs size 
from 63 to 93 nm. 
3. Drug Release: 
3.1. Determination of drug release profile from drug-loaded NPs: 
 NAC release profiles (Figures 21) obtained from duplicated runs were not reproducible 
and drug levels in the release compartment seems to fluctuate which is quiet unusual.  A 
possible reason for such abnormal results is the method of NAC quantification. NAC 
quantification using Ellman’s reagent depends on NAC’s sulfhydryl content. NAC thiol 
group is nucleophilic and easily oxidized, resulting in dimer formation, interfering with 
Elman’s reagent detection [79, 105].  It can be spotted that across time, fluctuations in 
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release percentage is obvious as a result of increasing NAC concentration in PBS with time, 
increasing the tendency of dimer formation. Thus, a decline in the release percentage is seen 
using Ellman’s reagent detection technique. For such reason new NPs were formulated 
using another model drug; FL. 
3.2. Determination of drug release profile from FL-loaded NPs in the 
absence of magnetic field: 
 When NAC was substituted by FL, the problem of complicated drug quantification was 
solved giving an improved release profile for free FL (control), FL-loaded CS NPs and FL-
loaded CS-MNPs. It is quite obvious from the chart (Figure 22) that encapsulation of FL 
into chitosan NPs retarded their release with only 5 % and 25 % of encapsulated FL released 
after 168 hours from CS NPs and CS-MNPs respectively compared to the control that 
provided 100 % release during the same period. A sustained drug release profile is very 
desirable since it allows for continuous exposure of cancer cells to drugs [106]. Release of 
surface adsorbed drug, diffusion of drug through a swollen rubbery matrix and release of 
drug upon surface erosion are the usual release mechanisms followed by polymeric 
particulate systems. Either one mechanism or more are followed [39, 107]. By visualizing 
the obtained chart, for CS-NPs both mechanisms seem to exist; an initial burst of FL is seen 
where 2 % is released in 1 hour followed by a slow, steady increase in the percent of FL 
released from NPs. For CS-MNPs the initial burst is absent indicating a lower prevalence of 
surface adsorbed drug.  
 The percentage of FL released from CS-MNPs was significantly higher than that of CS 
NPs. This was believed to be due to increased CS hydrogel porosity size as a result of multi-
core MNPs, the latter might be attributed to the interaction of MNP hydroxyls with chitosan 
amines, making them less available for TPP binding and accordingly yielding NPs with 
looser crosslinking and wider pores [99]. This contradicts the conclusion drawn by recent 
studies (Alexandre T Paulino, 2011 and Feng Xu, 2012) [108-109], however the size of FL-
loaded NPs showed a significant increase from 60 to 122 nm with MNPs incorporation, this 
suggests that encapsulation of MNPs affected CS NPs crosslinking. As a consequence the 
pore size of NP may have enlarged too resulting in faster release of FL from CS-MNPs.  
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3.3. Determination of MNPs effect on drug release upon the application of 
magnetic field: 
In preliminary experiments all samples showed a slow increase of the temperature after 
AMF exposure, resulting in an average temperature of 32 – 34 °C. This raise in temperature 
is mainly due to joule heating of the electrolyte solution [110]. Thus, the release profiles of 
FL-loaded CS NPs and FL-loaded CS-MNPs were compared among each other, and to 
those unexposed to HFMF, but maintained at constant temperature of 32°C. Figure 23a 
represents the logarithmic presentation for FL-loaded CS NPs, in which there is no 
significant difference in FL release upon the absence or presence of HFMF treatment is 
obvious. However, for FL-loaded CS-MNPs the logarithmic presentation (Figure 23b) 
showed that there is clear impact of the HFMF irradiation. The release of FL was faster 
under field influence. This was confirmed by calculated time constants (τ) (Figure 24) for 
both samples (FL-loaded CS NPs and CS-MNPs) and treatments (with and without HFMF) 
in which FL release was accelerated under field influence by a factor of 1.7, well beyond the 
experimental error. This indicates that MNPs played a role in accelerating drug release 
successfully. It can be explained as a result of magnetically induced stress where the 
oscillatory movement of MNPs within the CS NPs upon the application of an oscillating 
magnetic field resulted in the expansion of polymer chains; accelerating FL release [111-
113]. At the same time, it is verified that the sample temperature is ~ 32 °C in all performed 
experiments, thus ruling out a global thermal effect. thus, from this experiment, it can be 
determined that incorporation of MNPs will help in obtaining bolus release of drug; desired 
release profile for cancer treatment [9]. In addition, tailoring drug delivery will be possible 
for each patient by controlling drug release with magnetic field.  
4. NP modification: 
Cancer therapeutic device’s effectiveness is measured by its ability to eliminate tumor 
without deteriorating healthy tissue. Thus, targeted delivery of chemotherapeutic drug is 
essential in the success of the therapeutic device. Targeting will aid in increasing the 
specificity and internalization of the therapy thus, enhancing its efficiency while lowering 
the associated serious side effects always experienced by cancer patients. NP systems offer 
the quality of specificity and delivery of chemotherapeutic drugs, however active targeting 
can enhance this quality with cellular internalization. Active targeting involves the external 
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conjugation of targeting moieties to nanoparticles as represented by Figure 33 [114]. 
Knowing that 40-80% of non-small lung cancer (NSCLC) tissues overexpress epidermal 
growth factor receptor (EGFR), it proposed that the optimal targeting moieties for NSCLC 
will be either EGF or EGFR-antibody [114-115]. EGFR is a protein tyrosine kinase receptor 
from ErbB family that plays an essential role in signal transduction pathways that regulate 
key cellular functions such as proliferation and survival. Thus, targeting this receptor will be 
better using antibody as cell proliferation may be enhanced rather than inhibited by an free 
unbound or liberated EGF ligand [116].  
For efficient active targeting, the use of EDC as a cross-linker was considered as the 
convenient method for the reason that both types of NPs (CS NPs and CS-MNPs) expose 
CS’s amino groups [117]. Based on EDC’s mechanism of action it will induce amide bond 
formation specifically binding activated carboxylic group of IgG-FITC to CS’s amino group 
based on previously mentioned procedure. Since, the amount of IgG-FITC binding to NPs 
depend on number of amino groups, the concentration of tagged IgG-FITC differs for CS 
NPs and CS-MNPs as seen in Chapter 3-section 4.This suggests that CS content or 
available amines are lower in CS-MNPs than CS NPs. This supports the proposed 
hypothesis as to why drug loading of CS-MNPs was lower than that of CS NPs and FL 
release from CS-MNPs (in the absence of HFMF) is faster than with CS-NPs. For 
hypothesis confirmation, further quantification of CS yield can be performed in the future. 
5. NP-cell interaction: 
NP uptake begins with the initial adsorption of the NPs on to the cell membrane. This is 
followed by mostly an energy-dependent uptake process, which allows the NPs to be 
internalized into the cell and further trafficked to different subcellular locations[118]. 
Several studies have been conducted to determine the rate and extent of NP internalization 
into cells and its dependency on NP size, physicochemical properties and concentration 
[119-121] as well as the mechanisms involved in such process [119, 121-125]. Established 
techniques involve inductively coupled plasma (ICP) spectroscopies such as ICP mass 
spectrometry, fluorescence activated cell sorting/scanning (FACS), and methods employing 
fluorometric analysis of intact or lysed cells [126]. 
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5.1. MTT assay: 
The effect of synthesized nanoparticles on cell viability and proliferation is an essential 
study of cellular response to external factors. A widely accepted and reliable method to 
examine cell proliferation is via tetrazolium salts reduction. Metabolically active cells 
reduce yellow tetrazolium MTT into purple formazan. These formazan crystals are found 
intracellularly and can be released and solubilized by the addition of DMSO. The 
solubilized formazan is then quantified spectrophotometrically. For dead cells the 
absorbance of formazan will be lower than that for viable cells. Thus, the linear relationship 
between signal produced and cell number for each cell type is established. Therefore, an 
accurate quantification of changes in the rate of cell proliferation was allowed [127]. 
Figure 26 shows that CS NPs have a significant cytotoxic effect on lung cancer cells at 
concentration 2000 µg/ml where cell viability reached ~ 70 %; while at the same 
concentration fibroblast viability was ~ 90 %. This proves that CS NPs specifically possess 
cytotoxicity towards cancer cells and that they are biocompatible and non-toxic for normal 
cells [128-132]. This is due to that cancer cells possess highly negative surface in contrast to 
normal cells, thus accordingly increased cell membrane binding and uptake from cationic 
NPs for cancer cells will be visualized [126, 133]. MNPs showed to possess significant 
cytotoxicity at concentration of 200 µg/ml for both cell types. As mentioned by Caixia Fan 
(2011), this could be due to DNA damage, lipid and protein peroxidation, induced by 
reactive oxygen species developed as a result of free iron ions release [134]. However, this 
is not considered as a threat since sufficient cellular uptake was obtained at lower MNPs 
concentrations. Their cytotoxicity has additionally been evidently lowered through CS 
encapsulation. Therefore, the possibility of using the obtained formulation (CS-MNPs) for 
targeted delivery of chemotherapeutic drugs in-vivo is strongly supported since naked 
MNPs are not the intended therapeutic formulation. 
5.2. Extent of NP uptake determination; effect of NP: 
The extent of NP uptake in A549 lung cancer cells was studied as a function of NP 
concentration and Ab modification. Based on the Ab’s structure presented in Figure 34 it 
was important to perform EGFR-Ab-NP linkage at Fc region of the Ab, to ensure high 
cancer tissue specificity and minimal uptake of NPs by normal tissues; leaving the antigen-
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binding site (Fab region) free for EGFR interaction in cellular uptake. This was achieved 
through following the tagging methodology mentioned above in Chapter 2-section 2.4.1. 
Tagging Ab through Fc region was conducted by several studies [135-136]. Trials such as 
(Sarbari Acharya, 2009 and Petra Kocbek, 2007) [137-138] involved crosslinking between 
Abs’ amino groups and NPs carboxylic groups risking interference with Ab active binding 
site [138-139].  
Figure 27 shows that increasing the NPs concentration added, increases NPs 
concentration uptaken significanlty for both CS NPs and CS-MNPs whether non-tagged or 
tagged with Ab. However, the uptake of non-tagged NPs is significantly higher than 
corresponding tagged NPs. The incorporation of Ab reduced the uptake of CS NPs by 0.4 
and 0.7 folds for concentrations 150 and 250 µg/ml; respectively.  As for CS-MNPs the 
incorporation of Ab reduced uptake by 0.5 folds for both concentrations. This could be a 
consequence of  increased NPs size via high molecular weight Ab;from 60 to 122 nm and 
from 122 to 255 nm for FL-loaded CS NPs and CS-MNPs; respectively. Abs are large 
molecules, increase in NP’s size with Ab tagging has been repeatdly reported [135, 140-
141]. In addtion to size increase, a change in the nature of  protein corona formed around 
the NPs due to presnce of Ab, might be limiting cellular uptake of NPs [142-144] since the 
nature of adsorbed serum proteins depends grealty on the NP surface chemsitry [145]. 
Single chain EGFR-Abs fragments (known as single chain variable fragment, scFv) are of 
size range 25 to 28 KDa that is 80 % smaller in size from intact Abs (150 KDa). They 
usually consist of light and heavy chain variable domains joined with peptide linker. Thus, 
maintaining high binding affinity and cancer cell specificty [146]. ScFv  are highly 
recommended for future NPs targeting because not only is the NP uptake enhanced as a 
result of their low molecular weight, small size and high specificty in cancer cells targeting 
(due to abscence of Fc region), but they are also of lower cost than whole antibodies [115, 
147-148]. Furthermore, significanlty higher cellular upatke was attained by CS NPs in 
comparison to CS-MNPs. Cellular uptake of NPs are affected by several factors including: 
NPs size, charge, and concentration. Since they are both positively charged, then the uptake 
difference can be attributed to CS-MNPs size enlargement as a result of MNPs 
incorporation [149-151].  
 43 
 
To further confrim  unmodifed NP uptake, CLSM was used (Figure 28).  The control 
cells, in abnsence of NPs show WGA labelleing  (red) of their cell membranes. (Figure 
28a). As seen by Figure 28b NPs have escaped lysosome encapsulation preferentially 
exhibiting perinulclear co-localization as expected which is essential for the delivery of anti-
cancer therapeutics [149, 151-152]. WGA-AF is a cationic dye with high affinity to sialic 
acid and N-acetylglucosaminyl residue therefore, used to label cell membranes [153-154]. 
However, in the presence of chitosan, WGA preferentially labels chitosan NPs[126]. Since 
fixation was performed with ice cold methanol, cells were also permeablized enabling the 
WGA-AF to go into the cell and label CS NPs present intracellularly (Figure 28c ) [126]. 
Thus, in Figure 28c in the presence of WGA only labels CS NPs showing a rather different 
pattern than that seen in Figure 28(a). It is quiet important to note that green fluorescence 
from FL-loaded NPs seems to completely co-localize with WGA red florescence indicating  
that green dots seen are actually internalized NPs rather than noise.  
5.3. Efficiency of Cisplatin-loaded NPs via MTT assay: 
Figure 29 shows lower cytotoxicity of cisplatin loaded in NPs in comparison to free 
cisplatin of the same concentrations. This can be owed to sustained release profile 
characteristic for hydrogel NPs where small concentrations were released. Despite 
equivalent amount of cisplatin that should have been released after 24 hr from each NP 
represented cytotoxic effect, release of cisplatin from NPs within the cell could be actually 
quite different than the in-vitro release experiment. In-vitro experiments are generally 
conducted to prove the ability of formulation to release the drug, however actual release 
profiles are not exact replica due to different condition in the cell that could have not been 
simulated in in-vitro experiment. 
6. SFD and evaluation of Lung deposition by NGI: 
6.1. Incorporation of NPs in PVP: MD MPs: 
SFD technique is used for the development of uniformly sized microparticles. This 
technique is favored in contrast to most commonly used techniques; dry powder coating, 
oppositely charge NPs flocculation, spray drying fluidized bed granulation and spray drying 
as it does not expose the drug to harsh synthetic procedures that may adversely affect it’s 
therapeutic efficiency [155]. In Figure 30, the SEM images of both CS NPs and CS-MNPs 
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show that both of them are spherical in shape with nearly the same size of approximately 3 
µm. Obtaining microparticles of the same size was due to the SFD technique itself, since 
size of particles depend mainly on the size of the nozzle from which droplets are released 
and less on the initial size of the particle [156-157].   
6.2. Evaluation of aerodynamic properties of MPs using NGI: 
NPs represented different MMAD values. A possible reason for the higher MMAD for 
CS-MNPs is the higher density imposed by the MNPs, since MMAD is greatly affected by 
density [158]. Particle deposition is a function of its AD. Particles with ADs > 5µm deposit 
mainly in the large airways and oropharynx by inertial impaction, where they will be 
probably cleared via mucocillary clearance rather than reaching the lung [32]. Particles with 
ADs ranging from 1-5µm deposit by gravitational sedimentation and diffusion deeper into 
the lungs [31-32, 34-35] making the formulated NPs suitable drug delivery candidates to the 
lung. 
For both NPs, a very small amount seems to be retained in the capsule and similarly in 
the mouth as indicated by amount present in capsules and in mouth piece from the 
recovered dose in Figure 31. Approximately 37 % of the inhaled dose for both NPs was 
deposited in the trachea. However, ~50 % were deposited past the trachea where the 
majority of NSCLC occurs [159]. This ensures the minimum systemic delivery of drug due 
to lack of deposition of NPs in the alveolar region. Particles have also possessed fine 
particle fraction (FPF≤ 5.2 µm) of ~40 % indicating successful delivery to deep lung tissue. 
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Conclusions and Future Perspectives 
In conclusion, lung cancer is the deadliest solid tumor among all types of cancer. The 
number of cases and deaths caused cancer is exponentially increasing by time. This is due to 
poor diagnosis and exposure of the largest surface area of the body to carcinogenic 
substance through inhalation route. Despite the development of various chemotherapeutic 
drug delivery platforms, still the optimum formulation has not been achieved. The optimum 
route of chemotherapeutic drug delivery was thought to be inhalation since it lacks systemic 
toxicity and invasiveness experienced by I.V. route as well as patient inconvenience with 
endobronchial route. The combination of initial spike dose of chemotherapy followed by 
sustained supply of the drug was thought to provide an efficient therapeutic platform for 
tumor eradication and recurrence prevention. Thus, based on these thoughts a non-invasive, 
patient convenient platform for the targeted delivery of chemotherapeutic drugs to cancer in 
deeper lung tissue was developed and studied. The formulation consisted of inhalable MD-
based MPs obtained by SFD. These MPs were either encapsulating CS NPs loaded with 
MNPs and a chemotherapeutic drug or chemotherapeutic drug only. MNPs prepared were 
USPIONs of size 5 nm. They have enhanced drug release by 1.7 fold in response to external 
magnetic field. CS possessed sustained drug release profile in which only 5 and 25% of 
loaded FL were released in one week from CS NPs and CS-MNPs; respectively. CS NPs 
showed preferential toxicity to tumor cells (A549) in comparison to cultured fibroblasts 
(L929). Modification of CS NPs with Abs hindered their uptake by the cells in comparison 
to un-modified NPs due to enlargement of NPs size associated with Ab labeling.  The 
prepared SFD powders had fine particle fraction (FPF≤5.2 µm) of ~40 % w/w and MMAD 
of 5-6 µm as determined by the NGI. The targeted delivery to the lung cancer using the 
developed formulation seems to be a promising approach.  
For future studies, release profile of NPs for cisplatin should be examined to determine 
whether release profile is dependent or independent on type of drug encapsulated. 
Application of bolus drug release using HFMF induction generator with cisplatin-loaded 
NPs in-vitro on lung cancer cells (A549) should be tested to study the effect of exposure to 
spike drug concentrations on cells. Imaging properties of MNPs should be determined for 
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diagnostic purposes. Targeted delivery of NPs using whole Abs versus Ab fragments should 
be studied and compared. The effect of cisplatin-loaded NPs (with and without magnetic 
field) on tumor growth inhibition and recurrence prevention in-vivo on tumor A549 cell 
tumor bearing mouse should be examined. Optimization of MNPs content for efficient bolus 
delivery of drug, MRI imaging and deep lung deposition (since AD depends on the 
particle’s density) should be essentially evaluated. Stability of dry MPs powder and NPs 
should be studied to investigate the long-term effect on the stability of the biodegradable 
materials. Long-term effects of MNPs on animals should be tested to ensure minimized 
cytotoxicity in-vivo.     
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Tables 
Table 1: Recently developed biodegradable NP/MP drug delivery platforms used in lung cancer targeting. 
References Formulation 
Route of 
administratio
n 
Formulation Evaluation Findings 
Choi, S.H., 
et al [53] 
Self-assembled 
DOX-conjugated 
albumin NPs 
containing 
apoptotic TRAIL 
proteins 
Inhalation- 
Aerosolizer 
- In-vitro H226 
uptake of NPs 
- In-vivo uptake in an 
H226 cell tumor-
bearing mouse 
model. 
- Synergistic anti-cancer efficacy in-vitro and in-
vivo due to DOX and TRAIL.  
- New inhalable approach for treating resistant lung 
cancer. 
Long, J.T., 
et al [54] 
EGF-modified 
gelatin NPs 
(EGNP) loaded 
with DOX. 
 
Inhalation -
Nebulization 
- In-vitro A549 and 
H226 uptake of 
NPs. 
- In-vivo uptake in an 
A549 cell tumor-
bearing mouse 
model. 
- EGF-modified NPs possessed high targeting and 
cytotoxicity towards lung cancer cells in-vitro and 
in-vivo. 
Kaminskas, 
L.M., et al 
PEGylated 
dendrimers loaded 
Intratracheal 
-Instillation 
- In-vitro MAT 
13762 IIIB uptake 
- Efficiently potent inhibitory of cell and tumor 
growth in-vitro and in-vivo. 
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[55] with DOX. of dendrimers. 
- In-vivo uptake in a 
MAT 13762 IIIB 
cell tumor-bearing 
mouse model. 
Guo, X., et 
al [56] 
2-ME-loaded 
PLGA NPs coated 
with Chitosan 
Inhalation- 
Dry powder 
- In-vitro A549 and 
SPC-A1 uptake of 
NPs. 
- Spray-freeze dried NPs possessed desirable 
inhalation properties (high fine particle fraction 
and rough surfaces). 
- Significantly high antitumor efficiency was 
achieved by proposed platform compared to free 
drug combination or drug-free NPs. 
- Deposition to deep lung tissue was achieved with 
absence of irritation. 
Xu, H., et 
al [57] 
Tet-loaded PVP-
b-PCL NPs 
Not 
mentioned 
- In-vitro A549 
uptake of NPs. 
- Inhibition of cell growth, migration and invasion 
was enhanced through NPs in contrast to free Tet. 
Sun, Q., et 
al [58] 
Gelatin/DHA and 
HA/DHA NPs 
aggregates 
Not 
mentioned 
- In-vitro A549 
uptake of NPs. 
- Cancer cell death was significant after 2 days. 
Zhao, T., et 
al [59] 
(PTX-loaded 
(PGA-co-PCL)c-
Intratumoral   - In-vitro A549 
uptake of NPs.  
- In-vivo uptake in an 
- Drug release enhanced by the incorporation of 
hydrophilic PCL. 
- Tumor and cell growth were more effectively 
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b-TPGS2k NPs) A-549 cell tumor-
bearing mouse 
model.  
inhibited by (PGA-co-PCL)-b-TPGS2k NPs in 
comparison to free Taxol.  
Shen, J., et 
al [60] 
Hollow 
mesoporous silica 
nanospheres 
(HMSNs)  
encapsulating 
Bortezomib 
I.V. - In-vitro H1299 
uptake of NPs. 
- In-vivo uptake in a 
H1299 cell tumor-
bearing mouse 
model. 
- Tumor and cell growth were more effectively 
inhibited by Bortezomib-loaded HMSNs in 
comparison to free Bortezomib. 
Lv, S., et al 
[61] 
mPEsG-b-PLG-b-
PLL/DOCA NPs 
encapsulating 
DOX and PTX 
I.V. - In-vitro A549 
uptake of NPs.  
- In-vivo uptake in an 
A549 cell tumor-
bearing mouse 
model. 
- Significantly high antitumor efficiency was 
achieved by Co-NPs platform compared to free 
drug combination or single drug-loaded NPs with 
absence of side effects. 
Li, M., et al 
[62] 
DOX-loaded 
CMC NPs + 
Endostar 
I.V. - In-vitro A549 
uptake of NPs.  
- In-vivo uptake in an 
A-549 cell tumor-
bearing mouse 
model. 
- Surface functionalized CMC NPs for stealth 
purpose were prepared by simple procedure. 
- High DOX loading. 
- Efficient delivery and inhibitory effect of NPs in-
vitro and in-vivo.  
- Synergistic effect was achieved with co-
administered endostar. 
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Maya, S., 
et al [63] 
Chitosan cross-
linked (γ-PGA) 
NPs loaded with 
DTXL and 
decorated with 
CET 
Not 
mentioned 
- In-vitro A549 
uptake of NPs. 
- Enhanced cancer cell death by targeted NPs was 
determined by cytotoxicity assays as a result of 
DTXL selective delivery in comparison to non-
targeted NPs and normal cell lines (NIH3T3). 
Sadhukha, 
T., et al 
[64] 
EGFR-targeted, 
SPIO NPs (≈AD 
1.1 µm) 
Inhalation- 
Aerosolizer 
- In-vitro A549 
uptake of NPs.  
- In-vivo uptake in 
Metastatic Lung 
Cancer Model in 
SCID-bg Mice. 
- EGFR-targeting enhances tumor retention of SPIO 
NPs.  
- Significant inhibitory effect to tumor growth in-
vivo was achieved via magnetic hyperthermia. 
- Efficient therapeutic concentration was 
successfully delivered to the lung.  
Nejati-
Koshki, K., 
et al [65] 
Cisplatin-loaded 
Fe3O4 NPs 
modified with 
PLGA-PEG6000 
copolymers 
Not 
mentioned 
- In-vitro A549 
uptake of NPs.  
 
- Therapeutic potency was achieved in-vitro.  
Karra, N., 
et al [66] 
Antibody-tagged 
PLGA NPs loaded 
with PTX 
Palmitate 
I.V. - In-vitro A549-luc-
C8 uptake of NPs. 
- In-vivo uptake in 
Metastatic Lung 
- Surface functionalized PLGA NPs for antibody 
tagging were developed through simple procedure. 
- Efficient targeting and cytotoxicity to lung cancer 
cells in vitro was achieved through antibody 
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Cancer Model in 
SCID-bg Mice. 
labeling.  
- In-vivo therapeutic potential and tolerability was 
experienced. 
Yordanov, 
G., et al 
[67] 
Epirubicin-loaded 
PBCA NPs 
I.V. - In-vitro A549 
uptake of NPs.  
 
- Drug loaded efficiently (60-70 %). 
- NPs possessed significant cytotoxicity towards 
lung cancer cells in comparison to free drug. 
Meenach, 
S.A., et al 
[68] 
PEGylated 
phospholipid MPs 
loaded with PTX 
Inhalation- 
Dry powder 
- Next Generation 
Impactor (NGI) 
- Platform suitable for PTX delivery to the middle 
and deep regions of the lungs in a targeted fashion.  
McBride, 
A.A., et al 
[69] 
Lactose MPs 
loaded with SPIO 
NPs and DOX 
Inhalation-
Dry powder 
- NGI - Spray-freeze dried SPIONs with very high 
saturation magnetization had the potential to be 
targeted to specific regions of the lung using an 
external magnet. 
Patel, A.R., 
et al [70] 
Celecoxib 
encapsulated 
Nanolipidcarriers 
+ I.V. DTXL 
Inhalation- 
Aerosolizer 
- In-vivo uptake in an 
A549 cell tumor-
bearing mouse 
model. 
- Significant inhibitory effect on tumour growth was 
achieved via aerosolized Cxb-NLCs due to 
increase in lung residence time. 
- Aerosolized Cxb-NLC enhanced the therapeutic 
activity of Doc. 
Srinivasan, 
A.R., et al 
[71] 
Self-associated 
bevacizumab NPs 
Not 
mentioned 
- In-vitro A549 
uptake of NPs. 
- NPs have shown to possess high targeting 
specificity towards lung cancer cells.  
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Yin, H., et 
al [72] 
(mPEG)–PCL 
NPs encapsulating 
curcumin 
Not 
mentioned 
- In-vitro A549 
uptake of NPs. 
- Cancer cell death was more efficient for curcumin-
loaded (mPEG)–PCL NPs in comparison to free 
curcumin. 
Wang, P., 
et al [73] 
Curcumin-loaded 
SLPs 
Oral or I.V. - In-vitro A549 
uptake of NPs. 
- In-vivo uptake in an 
A549 cell tumor-
bearing mouse 
model. 
- Inhibited cell and tumor growth was achieved more 
efficiently for curcumin-loaded SLPs in 
comparison to free curcumin. 
Garg, N.K., 
et al [74] 
Gemcitabine 
loaded PEG-
chitosan NPs 
tagged with 
NSCLS specific 
anisamide 
I.V. - In-vitro A549 
uptake of NPs. 
- In-vivo uptake in an 
A549 cell tumor-
bearing mouse 
model. 
- Efficient targeting and inhibitory effect of NPs in-
vitro and in-vivo towards cell and tumor growth. 
Karthikeya
n, S., et al 
[75] 
Resveratrol  
loaded gelatin 
NPs 
I.V. - In-vitro NCI-H460 
cells uptake of NPs. 
- In-vivo uptake in a 
NCI-H460 ell 
tumor-bearing 
mouse model. 
- Anti-tumor activity is enhanced by NPs in 
comparison to free Resveratrol with reduced side 
effects. 
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Roa, W.H., 
et al [76] 
DOX in PACA 
NPs embedded in 
effervescent and 
non-effervescent 
MPs (≈AD 
3.4µm) 
Inhalation- 
Dry powder 
- In-vivo uptake in a 
H460 cell tumor-
bearing mouse 
model. 
- The formulation has the desired characteristics for 
airway targeting. 
- Significant anti-tumor effect was achieved through 
inhalation versus I.V with reduced side effects.  
Tseng, C.-
L., et al 
[77] 
Gelatin NPs 
tagged with 
NSCLS EGF. 
Inhalation- 
Nebulization 
- In-vivo uptake in an 
EGFR-
overexpressing cell 
tumor-bearing 
mouse model. 
- Aerosol droplets of a suitable MMAD were formed 
and showed enhanced deep lung tissue deposition. 
- Targeted delivery of NPs was achieved through 
EGF adsorption.  
Abbreviations: NPs: Nanoparticles, MPs: Microparticles, TRAIL: Tumor necrosis factor (TNF)-related apoptosis-inducing ligand, 
PACA: Poly alkylcyanoacrylate, DOX: Doxorubicin, EGF: Epidermal growth factor, PEG: Poly ethylene glycol, PBCA: Poly(butyl 
cyanoacrylate), PEITC: Phenethyl isothiocyanate, CDDP: Cisplatin, SPIO: Superparamagnetic Iron Oxide, MMAD: Mass Median 
Aerodynamic Diameter, 2-ME: 2-methoxyestradiol, PLGA: Poly(lactic-co-glycolic acid), MNPs: Magnetic nanoparticles, γ– PGA: 
γ-poly(glutamic acid), DTXL: Docetaxel, CET: Cetuximab, PTX: Paclitaxel, PCL: Poly-ɛ-caprolactone, TPGS2k: D-α-tocopheryl 
polyethylene glycol 2000 succinate, mPEG: Methoxy poly(ethylene glycol), Tet: Tetrandrine, PVP: Poly(N-vinylpyrrolidone), HA: 
Hyaluronan, DHA: Dihydroartemisinin, DOCA: Deoxycholate, PLL: Poly(l-lysine), SLP: Solid Lipid Nanoparticles, CMC: 
Carboxymethyl Cellulose. 
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Table 2: Opalescent NP formulations with varied parameters and their assessment 
using SEM. 
Protocol 
no. 
Details Observation Figure 
F1 
0.1% CS at pH 3 + 
0.04% TPP at pH 8 
Microparticles 12A 
F2 
0.1% CS at pH 4 + 
0.04% TPP at pH 5 
Aggregates 
12B 
F3 
0.1% CS at pH 4 + 
0.04% TPP at pH 8 
12C 
F4 
0.1% CS at pH 5 + 
0.04% TPP at pH 8 
12D 
F5 
0.3% CS at pH 3 + 
0.04% TPP at pH 8 
12E 
F6 
0.5% CS at pH 3 + 
0.04% TPP at pH 5 
12F 
F7 
0.5% CS at pH 3 + 
0.04% TPP at pH 8 
12G 
F8 
0.5% CS at pH 4 + 
0.04% TPP at pH 5 
12H 
F9 
0.1% CS at pH 5 + 
0.04% TPP at pH 5 
 
Small nanoparticles 
12I 
F10 
0.1% CS at pH 5 + 
0.08% TPP at pH 5 
12J 
F11 
0.1% CS at pH 5 + 
0.1% TPP at pH 5 
12K 
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Table 3: Further analysis of NPs (formulas 9-11) using DLS. 
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Table 4: Various formulations for MNPs synthesized with varied parameters that 
were attracted by externally applied magnet. 
Protocol 
no. 
Details 
F1 
0.1 M FeCl3.6H2O + 0.45 M NaHCO3 + 0.0167 M Vit C 
Autoclave at 150°C for 4 hrs. 
F2 
0.1 M FeCl3.6H2O + 0.45 M NaHCO3 + 0.6 M Vit C 
Autoclave at 150°C for 4 hrs. 
F3 
0.1 M FeCl3.6H2O + 0.45 M NaHCO3 + 0.1 M Vit C 
Autoclave at 150°C for 4 hrs. 
F4 
0.1 M FeCl3.6H2O + 0.45 M NaHCO3 + 0.1 M Vit C 
Autoclave at 200°C for 6 hrs. 
F5 
0.3 M FeCl3.6H2O + 0.45 M NaHCO3 + 1.8 M Vit C 
Autoclave at 150°C for 4 hrs. 
F6 
0.3 M FeCl3.6H2O + 0.45 M NaHCO3 + 1.8 M Vit C 
Autoclave at 200°C for 6 hrs. 
F7 
0.3 M FeCl3.6H2O + 0.45 M NaHCO3 + 0.3 M Vit C 
Autoclave at 150°C for 4 hrs. 
F8 
0.3 M FeCl3.6H2O + 0.45 M NaHCO3 + 0.3 M Vit C 
Autoclave at 200°C for 6 hrs. 
F9 
0.3 M FeCl3.6H2O + 0.45 M NaHCO3 + 0.15 M Vit C 
Autoclave at 200°C for 6 hrs. 
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Table 5: Mean size and potential for different MNPs formulations. 
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Table 6: Different Concentrations of AC with their corresponding CS NPs EE %. 
Concentration (mg/ml) Samples Entrapped Concentration (mg/ml) 
 
Mean 
± S.D 
7 
1 3.22 
2.9±0.5 
1' 2.51 
10 
2 4.06 
4.1±0.1 
2' 4.19 
12 
3 4.69 
5.6±1.2 
3' 6.42 
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Table 7: EE% and size comparison between the developed formula and same 
formulas in different studies. 
Drug EE% NP size Ref. 
N-acetylcysteine 41.3±0.9 63 ± 3 nm Our Formula 
Dextran-Doxrubcin 
complex 
60-65 100±10 nm [102] 
5-fluorouracil 
69.69±0.3 243±18 nm 
[103] 31.23±0.9 87±1 nm 
29.98±0.8 69±1 nm 
Levofloxacin 24.91 140 nm [104] 
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Figures 
 
 
 
Figure 1: Cancer Worldwide- International Agency for Research on Cancer and Cancer 
Research UK. World Cancer Factsheet. Cancer Research UK, London, 2014. 
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Figure 2: TNM staging for NSCLC- “T1= ≤3 cm in greatest dimension; T2= 3 cm in 
greatest dimension; T3 = any size with invasion of the chest wall, diaphragm, mediastinal 
pleura or parietal pericardium, or a tumor in the main bronchus (<2 cm distal to the 
carina) but without involvement in the carina, associated atelectasis or obstructive 
pneumonitis of the entire lung; T4 = any size with invasion of the mediastinum, heart, 
great vessels, trachea, esophagus, vertebral body or carina, or tumor with a malignant 
pleural or pericardial effusion, or with satellite tumor nodule(s) within the ipsilateral 
primary tumor lobe of the lung; N0 = no regional lymph node metastasis; N1= metastasis 
to ipsilateral peribronchial and/or ipsilateral hilar lymph nodes, and intrapulmonary 
nodes involved by direct extension of the primary tumor; N2 = metastasis to ipsilateral 
mediastinal and/or subcarinal lymph nodes(s); N3= metastasis to contralateral 
mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular 
lymph node(s); M0 = no distant metastasis; M1= distant metastasis present”- Carbone, 
D.P. and E. Felip, Adjuvant therapy in non-small cell lung cancer: future treatment 
prospects and paradigms. Clin Lung Cancer, 2011. 12(5): p. 261-71 
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Figure 3: Nanoparticles embedded in microparticles (NEMs) for airway tumor 
delivery- CS NPs encapsulating MNPs and chemotherapeutic drug and CS NPs 
encapsulating chemotherapeutic drug only tagged with tagging moiety are encapsulated 
separately in MPs. 
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Figure 4: Role of EGFR in cell growth and division- Growth ligands such as 
epidermal growth factor (EGF) and tumor growth factor alpha (TGF alpha) bind to 
EGFR inducing signaling cascades within the cell to promote cell division and growth- 
Retrieved from www.en.wikipedia.org, January, 2015. 
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Figure 5: Desirable release profile of chemotherapeutic drug from proposed 
formulation- Spike doses of chemotherapeutic drug are released from CS-MNPs upon 
alternating HFMF application as a stimulus to which MNPs respond, followed by 
sustained supply of chemotherapeutic drug from CS NPs. 
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Figure 6: Model Drugs: (a) N-acetyl cysteine (NAC) and (b) Fluorescein (FL) – 
Retrieved from www.wikimedia.org, June, 2014. 
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Figure 7: Indirect determination of N-acetyl cysteine (NAC) using Ellman's reagent- 
Ellman’s reagent reacts with free sulfhydryl group of NAC to produce dimer molecule 
and nitro-thiobenzoic acid that can be detected spectrophotometrically in the visible 
range. The absorbance of nitro-thiobenzoic acid is proportional to NAC concentration.  
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Figure 8: Cisplatin- Retrieved from www.wikimedia.org, December, 2014. 
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At assigned time intervals, 
samples were withdrawn from 
release compartment and 
replaced with fresh PBS 
 Released drug 
quantified 
Figure 9: Drug release profile determination from Drug-loaded NPs- Experimental 
Design in which purified NPs are placed in the dialysis membrane of the float-a-lyzer which 
is then placed in PBS-containing compartment that is eventually placed in a shaking 
incubator at 37°C. At specified time intervals aliquots from PBS are taken where drug was 
released to be quantified. 
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Figure 10: EDC (carbodiimide) cross-linking reaction scheme- EDC will work by 
activating carboxylic group of Ab forming active ester which upon NPs addition will 
allow the formation of amide bond between the carboxylic group of Ab and amino group 
of NPs- Hayworth, D. Carbodiimide Crosslinker Chemistry. Retrieved, August 2014. 
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Figure 11: Spray Freeze Drying (SFD) apparatus [80]- CS NPs and CS-MNPs placed 
in PVP:MD solution are fed by pressurized air through 2-fluid nozzle into spray tower 
cooled by liquid nitrogen-containing jacket covering the spray tower. MPs formed are 
then collected at the end of the spray tower in a cooled beaker which will then undergo 
lyophilization. 
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Figure 37- NGI Assembly- Retrieved from 
www.solvias.com/sites/default/files/solvias_prospects_02_201
2_web.pdf, December, 2014.
Figure 12: NGI Assembly (Induction port, Preseparator, Stages 1-7 and MOC) – Dry 
Powder will be moving from DPI placed at the mouth adaptor along the whole apparatus 
from the left to the right when vacuum is turned on. Particles will then deposit in different 
compartments of the NGI based on the AD cutoffs- Retrieved from 
www.solvias.com/sites/default/files/solvias_prospects_02_2012_web.pdf, December, 2014. 
 72 
 
 
Figure 13: Initial assessment of formulated NPs using SEM (Magnifications: 12.34, 
349.97, 372.49, 48.54, 71.86, 52.20, 243.21, 223.80, 67.52, 46.92 and 29.08 K X for A, 
B, C, D, E, F, G, H, I, J and K respectively)- Microparticles, aggregates and small-sized 
NPs are formed. 
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Figure 14: AFM analysis for formula 11 (CS NPs)- NPs size are determined by height 
and lateral dimensions measurement using AFM. 
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Figure 15: STEM image for prepared MNPs (formula 8) in DI water. 
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Figure 16: FT-IR of (a) MNPs and (b) Precursors (vitamin C and FeCl3.6H2O) with 
product (MNPs)-  
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Figure 17: Hysteresis loop of prepared MNPs powder (formula 8) measured using 
VSM at room temperature. 
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Figure 18: XRD chart showing the crystal structure of prepared MNPs (formula 8). 
The lines correspond to the profile of the magnetic cubic phase (JCPDS-ICDD Card No. 
24-0081). 
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Figure 19: HR-TEM images for prepared MNPs-loaded CS NPs in DI water. 
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Figure 20: SEM images of drug-loaded CS NPs purified in DI water (Magnifications 37.43 
and 420.85 K X; respectively). 
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Figure 21: Figure 4- N-acetyl cysteine (NAC) drug release profile. There is a 
significant difference between the release of Control (free NAC) and NAC-loaded CS 
NPs (P<0.0001, n=2) 
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Figure 22: Fluorescein (FL) drug release profile. The release profiles of the three 
samples were normalized to total released amount of control. The release was 
significantly affected by the sample (P<0.0001, n=2). 
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Figure 23: Logarithmic presentation for the release profile of a) FL-loaded CS NPs 
and b) FL-loaded CS-MNPs. Samples were taken from float-a-lyzers at 32°C and upon 
application of HFMF. 
 
 
Figure 24: τ for CS NPs and CS-MNPs- At 32°C did not show any significance 
difference while τ for same NPs showed extremely significant difference (***P<0.001, 
n=3) upon the application of HFMF. 
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Figure 25: IgG-FITC calibration curve in DI water. From which the concentration of 
tagged IgG-FITC on CS NPs and CS-MNPs are determined. 
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Figure 26: MTT assay for (a) CS NPs, CS-MNPs and (b) MNPs on A549 and L929 
cell lines. The decrease of viability % with increasing the CS concentration is statistically 
significant (** P<0.01 for n=6) for A549 cell lines. For MNPs, significant decrease in % 
viability was observed at concentration=200 µg/ml (*P<0.05 for n=6) in both types of 
cells. 
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Figure 27: Cellular Uptake of tagged and non-tagged NPs for A549 cell lines. It is 
statistically significant that increasing the NPs concentration added, increases NPs 
concentration uptaken for both CS NPs and CS-MNPs whether tagged or not with AB 
(***P<0.001 for n=6, **P<0.01 for n=6 respectively). However, the uptake of non-
tagged NPs is significantly higher than corresponding tagged NPs (CS NPs: **P<0.01, 
*P<0.05 for n=6 and CS-MNPs: ***P<0.001 for n=6)  
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Figure 28: CLSM images for intact A549 cells (a) control cells; untreated with NPs 
and (b), (c) after uptake of unmodified FL-loaded CS NPs in 24 hrs incubation. Cell 
membrane, nucleus and nanoparticles were labeled with Hoechst (blue), WGA-AF (red) 
and FL (green) dyes; respectively. 
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Figure 29: MTT assay for free cisplatin versus NPs-loaded cisplatin and cisplatin 
released correspondingly to each NP for both concentrations. Cell viability 
decreased significantly with increased free cisplatin concentration (****P<0.0001, 
n=4). 
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Figure 30: SEM images for SFD NPs. 
 
Figure 31:The NGI dispersion results for CS NPs and CS-MNPs in different 
compartments based on MPs AD. Data presented as mean ± standard deviation (n = 3). 
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Figure 32: CS NPs preparation by Ionotropic Gelation- Inter and Intramolecular 
electrostatic interactions taking place between amino groups of CS and phosphate groups 
of TPP- Luis E. Chávez de Paz, et al., Antimicrobial Effect of Chitosan Nanoparticles on 
Streptococcus mutans Biofilms. APPLIED AND ENVIRONMENTAL 
MICROBIOLOGY, 2011. 77(11): p. 3892–3895. 
 
 
 
 
 
 
 
 
Figure 33: Active targeting moieties attached to the 
surface of nanoparticle- Retrieved from 
www.aparnabio.com/the-science/targetting, 
December, 2014. 
Figure 34: Schematic diagram of 
monoclonal antibody: 1) Fab region, 
2) Fc region, 3) Antigen-binding site- 
Retrieved from www.en.wikipedia.org, 
December, 2014. 
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